View Filing Data

$ 175,315

$ 97,030

$ 295,166

Earnings per common share

^[1]

$ 0.96

$ 0.54

$ 1.73

Shares used in computing earnings per common share

^[1]

$ 0.91

$ 0.52

$ 1.63

^[1]

183,220

178,542

170,652

Balances, value at Dec. 31, 2008

^[1]

191,806

186,074

181,164

[1]	Reflects the May 20, 2011, two-for-one stock split (refer to Note 1 for further discussion)

Statement of Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands

Total

Common Stock [Member]

Additional Paid-In Capital [Member]

^[1]

Treasury Stock at Cost [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Accumulated Deficit [Member]

Comprehensive Income [Member]

$ 247,001

$ 16

^[1]

$ 941,428

$ (1,260)

$ 2,947

$ (696,130)

$ 37,539

Balances, common shares at Dec. 31, 2008

^[1]

162,738

Balances, treasury shares at Dec. 31, 2008

Foreign currency translation

415

Net change in unrealized gains on marketable securities

Unrealized loss on pension obligation

(416)

Unrealized gain (loss) on hedging activities

(4,910)

Conversion of convertible notes to common stock, shares

^[1]

11,288

Conversion of convertible notes to common stock, value

89,893

$ 1

^[1]

89,892

Issuance of common stock from exercise of options, shares

3,128

^[1]

Issuance of common stock from exercise of options, value

29,317

30,733

$ (1,416)

Issuance of restricted common stock, shares

^[1]

511

Excess tax benefit from stock options, value

764

Share-based compensation expense

31,104

Balances, value at Dec. 31, 2009

295,166

688,356

$ 17

^[1]

1,093,921

$ (2,676)

(1,942)

(400,964)

290,277

Balances, common shares at Dec. 31, 2009

^[1]

177,665

Balances, treasury shares at Dec. 31, 2009

Foreign currency translation

(528)

Net change in unrealized gains on marketable securities

(12)

Unrealized loss on pension obligation

(1,898)

Unrealized gain (loss) on hedging activities

(2,760)

Conversion of convertible notes to common stock, shares

^[1]

788

Conversion of convertible notes to common stock, value

6,175

Issuance of common stock from exercise of options, shares

^[1]

3,292

Issuance of common stock from exercise of options, value

37,546

$ 1

^[1]

37,545

Issuance of restricted common stock, shares

^[1]

629

Excess tax benefit from stock options, value

1,970

Share-based compensation expense

33,857

Balances, value at Dec. 31, 2010

97,030

$ 859,736

$ 18

^[1]

1,173,468

$ (2,676)

(7,140)

(303,934)

91,832

Balances, common shares at Dec. 31, 2010

^[1]

182,374

Balances, treasury shares at Dec. 31, 2010

Foreign currency translation

$ (1,328)

(1,328)

Net change in unrealized gains on marketable securities

(10)

Unrealized loss on pension obligation

(1,165)

Unrealized gain (loss) on hedging activities

13,822

Costs associated with 2 for 1 stock split

(55)

Conversion of convertible notes to common stock, shares

^[1]

381

Conversion of convertible notes to common stock, value

$ 2,996

2,996

Issuance of common stock from exercise of options, shares

2,744

^[1]

Issuance of common stock from exercise of options, value

$ 35,821

$ 1

^[1]

35,820

Issuance of restricted common stock, shares

^[1]

117

Excess tax benefit from stock options, value

4,016

Share-based compensation expense

45,344

Balances, value at Dec. 31, 2011

175,315

$ 1,134,492

$ 19

^[1]

$ 1,261,589

$ (2,676)

$ 4,179

$ (128,619)

$ 186,634

Balances, common shares at Dec. 31, 2011

^[1]

185,616

Balances, treasury shares at Dec. 31, 2011

[1]	Reflects the May 20, 2011, two-for-one stock split (refer to Note 1 for further discussion)

Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statement of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net income	$ 175,315	$ 97,030	$ 295,166
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	17,616	15,792	12,473
Change in fair value of contingent consideration	1,400	0	0
Share-based compensation expense	44,763	32,338	28,731
Deferred taxes	42,066	36,389	(208,726)
Marketable securities premium amortization	(24)	960	0
Non-cash debt exchange expense	0	0	3,395
Unrealized foreign currency (gain) loss	5,516	(523)	(997)
Losses (gains) on forward contracts	479	6,205	(2,233)
Loss on disposal of property, plant and equipment	136	76	271
Changes in operating assets and liabilities, excluding the effect of acquisitions:
Accounts receivable	(78,778)	(59,239)	(36,440)
Inventories	(12,179)	(14,119)	14,596
Prepaid expenses and other assets	(21,040)	(2,773)	(6,926)
Accounts payable and accrued expenses	79,781	47,455	14,131
Deferred revenue	15,033	1,315	400
Net cash provided by operating activities	270,084	160,906	113,841
Cash flows from investing activities:
Purchases of marketable securities	0	(129,860)	(19,026)
Proceeds from maturity or sale of marketable securities	94,458	53,387	0
Purchases of property, plant and equipment	(21,982)	(12,823)	(35,275)
Purchase of technology rights	0	(20)	(27,740)
Payments for acquisitions of businesses, net of cash acquired	(105,886)	0	0
(Increase) decrease in restricted cash	(307)	(2)	618
Net cash used in investing activities	(33,717)	(89,318)	(81,423)
Cash flows from financing activities:
Debt issuance costs	0	0	(50)
Payments on capital leases	(731)	(649)	(301)
Payments on mortgage loan	0	0	(44,000)
Proceeds from revolving credit facility	60,000	0	0
Payments on revolving credit facility	(60,000)	0	0
Excess tax benefit from stock options	4,016	1,970	764
Payment of taxes in exchange of treasury shares	0	0	(1,416)
Net proceeds from the exercise of stock options	35,765	37,546	30,733
Net cash provided by (used in) financing activities	39,050	38,867	(14,270)
Effect of exchange rate changes on cash	(1,697)	(482)	1,012
Net change in cash and cash equivalents	273,720	109,973	19,160
Cash and cash equivalents at beginning of period	267,145	157,172	138,012
Cash and cash equivalents at end of period	540,865	267,145	157,172
Supplemental disclosures
Cash paid for interest (net of amounts capitalized)	538	500	4,282
Cash paid for income taxes	10,221	7,953	4,268
Supplemental cash flow disclosures from investing and financing activities:
Conversion of convertible debt	3,012	6,249	88,409
Equipment acquired through capital lease obligation	20	1,169	722
Contingent consideration issued in acquisitions	$ 16,720	$ 0	$ 0

Business Overview and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2011

Business Overview and Summary of Significant Accounting Policies [Abstract]

Business Overview and Summary of Significant Accounting Policies

Business

Alexion Pharmaceuticals, Inc. (“Alexion”, the “Company”, “we”, “our” or “us”) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. We are also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism, and we are progressing with other biotechnology product candidates in ultra-rare and severe disorders which are now in various stages of development. We were incorporated in 1992 and began commercial sale of Soliris in 2007.

Stock Split

On May 20, 2011, we effected a two-for-one stock split, paid in the form of a 100% stock dividend. Stockholders of record at the close of trading on May 2, 2011 were issued one additional share of common stock for each share owned by such shareholder. All share and per share data presented in the accompanying consolidated financial statements and notes has been retroactively restated to reflect the stock split.

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Alexion and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. On January 28, 2011, we acquired Taligen Therapeutics, Inc. Accordingly, all of the assets acquired and liabilities assumed were recorded at their respective fair values as of the date of the acquisition, and Taligen's results of operations are included in the consolidated financial statements from the date of acquisition. On February 8, 2011 we acquired certain patents and assets from Orphatec Pharmaceuticals GmbH. Accordingly, all of the assets acquired were recorded at their respective fair values as of the date of acquisition. See Note 2 for additional information regarding the acquisitions.

We have reclassified certain disclosure amounts for the prior period to conform to the current year presentation.

Dividend Policy

We have never paid a cash dividend on shares of our stock. We currently intend to retain our earnings to finance future operations and do not anticipate paying any cash dividends on our stock in the foreseeable future.

Critical Accounting Estimates

The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions.

The most significant areas involving estimates, judgments and assumptions used in the preparation of our consolidated financial statements are as follows:


•	Revenue recognition;


•	Contingent liabilities;


•	Inventories;


•	Research and development expenses;


•	Share-based compensation;


•	Valuation of goodwill, acquired intangible assets and in-process research and development (IPR&D);


•	Valuation of contingent consideration; and


•	Income taxes.

Foreign Currency Translation

The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders’ equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders’ equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost plus accrued interest, which approximates fair value, and include short-term highly liquid investments with original maturities of three months or less.

Fair Value of Financial Instruments

The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term maturities. Our derivative financial instruments are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk and our counterparties’ credit risks. Our marketable securities, all of which are available-for-sale, are valued based upon pricing of securities with similar investment characteristics and holdings. Our convertible notes and other debt obligations are carried at historical cost. Our contingent consideration liabilities related to the Taligen and Orphatec acquisitions are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met. See Notes 9 and 15 for fair value information.

Marketable Securities

We invest our excess cash balances in marketable securities of highly rated financial institutions and investment-grade debt instruments. We limit the amount of investment exposure as to institution, maturity and investment type. We classify our marketable securities as “available-for-sale” and, accordingly, record such securities at fair value.

Unrealized gains and losses that are deemed temporary are included in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. If any adjustment to fair value reflects a significant decline in the value of the security, we consider all available evidence to evaluate the extent to which the decline is “other than temporary” and would mark the security to market through a charge to our statement of operations. Credit losses are identified when we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security. In the event of a credit loss, only the amount associated with the credit loss is recognized in operating results, with the amount of loss relating to other factors recorded in accumulated other comprehensive income (loss).

Accounts Receivable

Our standard credit terms vary based on the country of sale and range from 30 to 120 days. Our consolidated average days’ sales outstanding ranges from 80 to 100 days. We sell Soliris to a limited number of customers, and we evaluate the creditworthiness of each such customer on a regular basis. In certain European countries, sales by us are subject to payment terms that are statutorily determined. This is primarily the case in countries where the payor is government-owned or government-funded, which we consider to be creditworthy. The length of time from sale to receipt of payment in certain countries typically exceeds our credit terms. In countries in which collections from customers extend beyond normal payment terms, we seek to collect interest. We record interest on customer receivables as interest income when collected. For non-interest bearing receivables with an estimated payment beyond one year, we discount the accounts receivable to present value at the date of sale, with a corresponding adjustment to revenue. Subsequent adjustments for further declines in credit rating are recorded as bad debt expense as a component of selling, general and administrative expense. We also use judgments as to our ability to collect outstanding receivables and provide allowances for the portion of receivables if and when collection becomes doubtful.

We continue to monitor economic conditions, including volatility associated with international economies, associated impacts on the financial markets and our business and the sovereign debt crisis in Europe. The credit and economic conditions in Greece, Italy, Spain and Portugal, among other members of the European Union have deteriorated throughout 2011. These conditions have resulted in, and may continue to result in, an increase in the average length of time it takes to collect our outstanding accounts receivable in these countries. As of December 31, 2011, our accounts receivable in Greece, Italy, Spain, Ireland and Portugal were approximately $83,400. Approximately $24,000 of this amount has been outstanding for greater than one year, and we have recorded an allowance of approximately $3,500 related to these receivables as of December 31, 2011.

In July 2011, we received non-interest bearing bonds issued by the Greek government that mature in 2012 and 2013 for payment on receivables from 2008 and 2009 as part of the Greek government's plan for its repayment of its debt to international pharmaceutical companies. We sold the bonds in July 2011.

During the year ended December 31, 2011, we have recorded bad debt expense of approximately $4,100 related to the reduction of value of Greek bonds and other reduction in the realizable value of our accounts receivable in these countries.

For the year ended December 31, 2011, two individual customers accounted for 18% and 13% of the accounts receivable balance and 19% and 12% of net product sales. For the year ended December 31, 2010, one individual customer accounted for 18% of the accounts receivable balance and 21% of net product sales. No other customers accounted for more than 10% of net product sales or accounts receivable.

Inventories

Inventories are stated at the lower of cost or estimated realizable value. We determine the cost of inventory using the weighted-average cost method.

The components of inventory are as follows:



	December 31,
	2011		2010
Raw materials	$	9,677	$	4,835
Work-in-process	37,000		37,312
Finished goods	34,709		20,018
	$	81,386	$	62,165

Capitalization of Inventory Costs

We capitalize inventory produced for commercial sale, including costs incurred prior to regulatory approval but subsequent to the filing of a Biologics License Application (BLA) when the Company has determined that the inventory has probable future economic benefit. Inventory is not capitalized prior to completion of a phase III clinical trial. For products with an approved indication, raw materials and purchased drug product associated with clinical development programs are included in inventory and charged to research and development expense when consumed. For products without and approved indication, purchased drug product is charged to research and development expense upon final quality release. We also capitalize the cost of inventory manufactured at our manufacturing plant in property, plant and equipment prior to the approval of the facility by regulatory authorities.

Inventory Write-Offs

We analyze our inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess of its estimated realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of our product is subject to strict quality control, certain batches or units of product may, after a period of time, no longer meet quality specifications or may expire, at which point we would adjust our inventory values. Soliris currently has a maximum estimated life of 48 months and, based on our sales forecasts, we expect to realize the carrying value of the Soliris inventory.

Derivative Instruments

We record the fair value of derivative instruments as either assets or liabilities on the balance sheet. The accounting for gains and losses resulting from changes in fair value is dependent on the use of the derivative and whether it is designated and qualifies for hedge accounting.

All qualifying hedging activities are documented at the inception of the hedge and must meet the definition of highly effective in offsetting changes to future cash. The effectiveness of the qualifying hedge contract is assessed quarterly. We record the fair value of the qualifying hedges in other current assets, other assets, other current liabilities and other liabilities. Gains or losses resulting from changes in the fair value of qualifying hedges are recorded in other comprehensive income (loss) until the forecasted transaction occurs. When the forecasted transaction occurs, this amount is reclassified into revenue. Any non-qualifying portion of the gains or losses resulting from changes in fair value, if any, is reported in other income and expense.

Prepaid Manufacturing Costs

Cash advances paid by us prior to receipt of the inventory are recorded as prepaid manufacturing costs. The cash advances are subject to forfeiture if we terminate the scheduled production. We expect the carrying value of the prepaid manufacturing costs to be fully realized.

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. We estimate economic lives as follows:


•	Building and improvements—five to thirty years


•	Machinery and laboratory equipment—three to twenty years


•	Computer hardware and software—two to five years


•	Furniture and office equipment—three to seven years

Leasehold improvements and assets under capital lease arrangements are amortized over the lesser of the estimated useful life or the term of the respective lease. Maintenance costs are expensed as incurred.

Construction-in-progress reflects amounts incurred for property, plant, or equipment construction or improvements that have not been placed in service.

Intangible Assets

Our intangible assets consist of licenses, patents, purchased technology and acquired in-process research and development (IPR&D). Intangible assets with definite lives are amortized over their estimated useful lives and reviewed for impairment if certain events occur as described in "Impairment of Long-Lived Assets" below. Intangible assets which are not amortized include acquired IPR&D. Amortization of acquired IPR&D will commence upon completion of the associated research and development efforts.

Goodwill

Goodwill represents the difference between the purchase price of acquired businesses and the fair value of their identifiable tangible and intangible net assets and is not amortized. Goodwill is reviewed for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill might not be recoverable. No impairment charges have occurred as a result of our annual impairment assessments. We test our goodwill annually for impairment on December 31.

Impairment of Long-Lived Assets

We evaluate our long-lived assets, which are primarily comprised of intangible assets and property, plant and equipment, for impairment whenever events or changes in circumstances indicate the carrying value of an asset or group of assets is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to future undiscounted net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. In addition, IPR&D is reviewed annually for impairment by comparing the fair value to the carrying value of the IPR&D. We did not recognize any impairment loss for long-lived assets during the years ended December 31, 2011, 2010 and 2009.

Contingent Liabilities

We are currently involved in various claims and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results.

Contingent Consideration

We record contingent consideration resulting from a business combination at its fair value on the acquisition date. On a quarterly basis, we revalue these obligations and record increases or decreases in their fair value as an adjustment to operating earnings. Changes to contingent consideration obligations can result from adjustments to discount rates, accretion of the discount rates due to the passage of time, updates in the assumed achievement or timing of any development or commercial milestones, changes in the probability of certain clinical events or changes in the assumed probability associated with regulatory approval. The assumptions related to determining the value of contingent consideration include a significant amount of judgment, and any changes in the assumptions could have a material impact on the amount of contingent consideration expense recorded in any given period.

Revenue Recognition

Our principal source of revenue is product sales. We recognize revenue from product sales when persuasive evidence of an arrangement exists, title to product and associated risk of loss has passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured and we have no further performance obligations. Revenue is recorded upon receipt of the product by the end customer, which is typically a hospital, physician’s office, private or government pharmacy or other health care facility. Amounts collected from customers and remitted to governmental authorities, such as value-added taxes (VAT) in foreign jurisdictions, are presented on a net basis in our statements of operations and do not impact net product sales.

In the United States, our customers are primarily specialty distributors and specialty pharmacies which supply physician office clinics, hospital outpatient clinics, infusion clinics or home health care providers. We also sell Soliris to government agencies. Outside the United States, our customers are primarily hospitals, hospital buying groups, pharmacies, other health care providers and distributors.

Because of factors such as the pricing of Soliris, the limited number of patients, the short period from product sale to patient infusion and the lack of contractual return rights, Soliris customers often carry limited inventory. We also monitor inventory within our sales channels to determine whether deferrals are appropriate based on factors such as inventory levels, contractual terms and financial strength of distributors. To date, actual refunds and returns have been negligible.

We have entered into volume-based arrangements with governments in certain countries in which reimbursement is limited to a contractual amount. We estimate incremental discounts resulting from these contractual limitations, based on estimated sales during the limited period, and we apply the discount percentage to product shipments as a reduction of revenue. In addition to sales in countries where Soliris is commercially available, we have also recorded revenue on sales for patients receiving Soliris treatment through named-patient programs. The relevant authorities or institutions in those countries have agreed to reimburse for product sold on a named-patient basis where Soliris has not received final approval for commercial sale.

We record estimated rebates payable under governmental programs, including Medicaid in the United States and other programs outside the United States, as a reduction of revenue at the time of product sale. Our calculations related to these rebate accruals require analysis of historical claim patterns and estimates of customer mix to determine which sales will be subject to rebates and the amount of such rebates. We update our estimates and assumptions each period and record any necessary adjustments, which may have an impact on revenue in the period in which the adjustment is made. Generally, the length of time between product sale and the processing and reporting of the rebates is three to six months.

We record distribution and other fees paid to our customers as a reduction of revenue, unless we receive an identifiable and separate benefit for the consideration and we can reasonably estimate the fair value of the benefit received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale.

We enter into foreign exchange forward contracts to hedge exposures resulting from portions of our forecasted intercompany revenues that are denominated in currencies other than the U.S. dollar. These hedges are designated as cash flow hedges upon inception. We record the effective portion of these cash flow hedges to revenue in the period in which the sale is made to an unrelated third party and the derivative contract is settled.

Research and Development Expenses

Research and development expenses are comprised of costs incurred in performing research and development activities including payroll and benefits, pre-clinical, clinical trial and related clinical manufacturing costs, manufacturing development and scale-up costs, product development and regulatory costs, contract services and other outside contractor costs, research license fees, depreciation and amortization of lab facilities, and lab supplies. These costs are expensed as incurred. We accrue costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the vendors that perform the services.

Share-Based Compensation

We have one share-based compensation plan known as the 2004 Incentive Plan. Under this plan, restricted stock, restricted stock units, stock options and other stock-related awards may be granted to our directors, officers, employees and consultants or advisors of the Company or any subsidiary. To date, share-based compensation issued under the plan consists of incentive and non-qualified stock options, restricted stock and restricted stock units. Stock options are granted to employees at exercise prices equal to the fair market value of our stock at the dates of grant. Generally, stock options, restricted stock and restricted stock units granted to employees fully vest four years from the grant date. Stock options have a contractual term of 10 years. We recognize share-based compensation expense, based on the fair value of stock awards, on a straight-line basis over the requisite service period of the individual grants, which typically equals the vesting period.

Earnings Per Common Share

Basic earnings per common share (EPS) are computed by dividing net income by the weighted-average number of shares of common stock outstanding. For purposes of calculating diluted EPS, net income is adjusted for the after-tax amount of interest and deferred financing costs associated with our convertible debt, and the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method, as well as the potential dilution if the remaining convertible notes were converted to common stock.

The following table summarizes the calculation of basic and diluted EPS for years ended December 31, 2011, 2010 and 2009:



	December 31,
	2011		2010		2009
Net income used for basic calculation	$	175,315	$	97,030	$	295,166
Weighted-average effect of dilutive securities:
Interest expense and debt financing cost amortization, net of tax, related to our 1.375% convertible senior notes	26		72		298
Net income used for diluted calculation	$	175,341	$	97,102	$	295,464
Shares used in computing earnings per common share—basic	183,220		178,542		170,652
Weighted-average effect of dilutive securities:
Shares issuable upon the assumed conversion of our 1.375% convertible senior notes	198		766		4,918
Stock awards	8,388		6,766		5,594
Dilutive potential common shares	8,586		7,532		10,512
Shares used in computing earnings per common share—diluted	191,806		186,074		181,164
Earnings per common share:
Basic	$	0.96	$	0.54	$	1.73
Diluted	$	0.91	$	0.52	$	1.63

The following table represents the potentially dilutive shares excluded from the calculation of EPS for the years ended December 31, 2011, 2010 and 2009 because their effect is anti-dilutive:



	December 31,
	2011	2010	2009
Potentially dilutive securities:
Options to purchase common stock	1,905	2,468	4,480
Unvested restricted stock and restricted stock units	15	6	14
	1,920	2,474	4,494

Income Taxes

We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. We provide a valuation allowance when it is more likely than not that deferred tax assets will not be realized. We recognize the benefit of an uncertain tax position that has been taken or we expect to take on income tax returns if such tax position is more likely than not to be sustained.

Comprehensive Income (Loss)

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) includes changes in equity that are excluded from net income (loss), such as foreign currency translation adjustments, changes in pension liabilities, unrealized holding gains and losses on available for sale securities and unrealized gains and losses on hedge contracts. Certain of these changes in equity are reflected net of tax.

A summary of accumulated other comprehensive income (loss) is summarized as follows:



	Pension Liability			Net Unrealized Gain(Loss) from Marketable Securities			Net Unrealized Gain(Loss) From Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income(Loss)
Balance December 31, 2009	$	(1,120	)	$	22		$	259		$	(1,103	)	$	(1,942	)
Period Change	(1,898		)	(12		)	(2,760		)	(528		)	(5,198		)
Balance December 31, 2010	$	(3,018	)	$	10		$	(2,501	)	$	(1,631	)	$	(7,140	)
Period Change	(1,165		)	(10		)	13,822			(1,328		)	11,319
Balance December 31, 2011	$	(4,183	)	$	—		$	11,321		$	(2,959	)	$	4,179

New Accounting Pronouncements

In May 2011, the Financial Accounting Standards Board (FASB) issued a new standard on fair value measurement and disclosure requirements. The new standard changes fair value measurement principles and disclosure requirements including measuring the fair value of financial instruments that are managed within a portfolio, the application of applying premiums and discounts in a fair value measurement, and additional disclosure about fair value measurements. The new standard is effective for interim and annual periods beginning after December 15, 2011. We do not expect a material impact with the adoption of this new standard.

In June 2011, the FASB issued a new standard on the presentation of comprehensive income. The new standard eliminated the current option to report other comprehensive income and its components in the statement of changes in equity. Under the new standard, companies can elect to present items of net income and other comprehensive income in one continuous statement or in two separate, but consecutive statements. The new standard is effective at the beginning of fiscal years beginning after December 15, 2011 and we will comply with this requirement in the first quarter 2012.

In September 2011, the FASB issued a new standard to simplify how an entity tests goodwill for impairment. The new standard allows companies an option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining if it is necessary to perform the two-step quantitative goodwill impairment test. Under the new standard, a company is no longer required to calculate the fair value of a reporting unit unless the company determines, based on the qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The new standard is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011.

Acquisitions

12 Months Ended

Dec. 31, 2011

Acquisitions [Abstract]

Acquisitions

Acquisition of Taligen Therapeutics, Inc.

On January 28, 2011, we acquired all of the outstanding capital stock of Taligen Therapeutics, Inc. (Taligen) in a transaction accounted for under the acquisition method of accounting for business combinations. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Taligen were recorded as of the acquisition date at their respective fair values. The reported consolidated financial condition after completion of the acquisition reflects these fair values. Taligen's results of operations are included in the consolidated financial statements from the date of acquisition.

We made initial payments of $111,773 in cash and may make additional future payments of up to $367,000 in contingent milestone payments. Prior to the acquisition, Taligen was a privately held development-stage biotechnology company involved in the development of preclinical compounds including product candidates for the potential treatment of patients with ophthalmic diseases such as age-related macular degeneration (AMD), as well as other novel antibody and protein regulators of the complement inflammatory pathways. We acquired Taligen to broaden our portfolio of preclinical compounds and to expand our capabilities in translational medicine.

During the year ended December 31, 2011, we incurred approximately $10,375, in costs related to the Taligen acquisition. Acquisition-related costs include the following:



	December 31, 2011
Separately-identifiable employee costs	$	6,597
Professional fees	2,728
Changes in fair value of contingent consideration	1,050
	$	10,375

The Taligen acquisition included contingent consideration which would obligate us to make up to $367,000 in cash milestone payments to the former Taligen shareholders upon achievement of various development and commercial milestones.

The initial fair value of contingent consideration was estimated at $11,634, which was recorded as a noncurrent liability. We determined the fair value of these obligations to pay additional milestone payments using various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a 10-year BBB industrial index rate of 4.9%, which is representative of a market participant assumption. The range of estimated milestone payments is from zero if no clinical milestones are achieved for any product to $367,000 if six products gain both U.S and European marketing approval.

Subsequent to the acquisition date, we have adjusted the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the passage of time as development work progresses towards the achievement of the milestones. At December 31, 2011, the fair value of the contingent consideration for Taligen was $12,684.

A reconciliation of upfront payments in accordance with the purchase agreement to the total purchase price is presented below:



	Taligen
Upfront payment in accordance with agreement	$	111,773
Separately-identifiable employee costs	(6,259		)
Total consideration transferred	$	105,514
Estimated fair value of contingent consideration	11,634
Total purchase price	$	117,148

The assets acquired and liabilities assumed at the acquisition date based upon their respective fair values are summarized below:



	Taligen
Cash and cash equivalents	$	2,678
Purchased technology	5,000
In-process research and development	59,500
Other assets	555
Assets acquired	67,733
Deferred tax liability (net)	(9,173		)
Other liabilities assumed	(1,084		)
Liabilities assumed	(10,257		)
Goodwill	59,672
Net assets acquired	$	117,148

Asset categories acquired in the Taligen acquisition included working capital, fixed assets, purchased technology and in-process research and development (IPR&D). The fair value of working capital was determined to approximate book values. Subsequent to the acquisition date, we adjusted the fair value of the contingent consideration and deferred tax liabilities in the purchase allocation by $908 related to circumstances in effect at the acquisition date, with a corresponding increase to goodwill.

Purchased technology includes a platform technology that can be used for the development of other compounds. The estimated fair value was determined using the relief from royalty method, an approach under which fair value is estimated to be the present value of royalties saved because we own the intangible asset and therefore do not have to pay a royalty for its use. Our estimated useful life of the purchased technology is 12 years.

Intangible assets associated with IPR&D projects relate to two preclinical Taligen product candidates. Management estimated the acquisition-date fair value of intangible assets related to IPR&D to be $59,500. The estimated fair value was determined using the cost approach. The cost approach estimates the costs that would be incurred to replace the assets being purchased. The fair value using the cost approach was dependent on an estimated rate of return on historical costs incurred of 25%, which represents a rate of return that a market participant would expect for these assets. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis, as well as between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts. If and when development is complete, which generally occurs when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents the goodwill amount resulting from the acquisition. We do not expect any portion of this goodwill to be deductible for tax purposes. The goodwill attributable to our acquisition of Taligen has been recorded as a noncurrent asset and is not amortized, but is subject to an annual review for impairment. The factors that contributed to the recognition of goodwill included the synergies that are specific to our business and not available to market participants, including our unique ability to leverage our knowledge in the areas of complement inhibition and rare diseases for the development of the Taligen compounds and technology, the acquisition of a talented workforce that brings translational medicine expertise to all of our preclinical compounds and our ability to utilize our research capacity to the development of additional compounds using acquired technology.

We recorded a deferred tax liability of $9,707. This amount was primarily comprised of $21,545 related to IPR&D, offset by acquired net operating losses and research credit carryovers totaling $11,838.

We have determined that separate presentation of Taligen's results of operations is impracticable for the year ended December 31, 2011 as results are not separately tracked due to the integration of Taligen into our operations upon acquisition.

Pro forma financial information (unaudited)

The following unaudited pro forma information presents the combined results of operations for the years ended December 31, 2011 and 2010 as if the acquisition of Taligen had been completed on January 1, 2010. The pro forma results do not reflect any material adjustments, operating efficiencies or potential cost savings which may result from the consolidation of operations.



	December 31,
	2011		2010
Revenues	$	783,431	$	541,413
Net income	174,209		84,662
Earnings per common share
Basic	$	0.95	$	0.47
Diluted	$	0.91	$	0.45

Acquisition of Orphatec Pharmaceuticals GmbH Assets

On February 8, 2011, we acquired certain patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec) related to an investigational therapy for patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare genetic disorder characterized by severe brain damage and rapid death in newborns. The acquisition was accounted for under the acquisition method of accounting for business combinations. Orphatec is a privately held development-stage biotechnology company with headquarters in Cologne, Germany.

We made initial payments of $3,050 in cash and may make additional future payments of up to $42,000 in contingent milestone payments. We will also make future payments to Orphatec for manufacturing, development, and other services, which we estimate to be at a rate that approximates fair value. We acquired these assets to advance our mission to provide life-transforming treatments for patients with severe and life-threatening disease states.

During the year ended December 31, 2011, we incurred approximately $1,072 in costs related to the Orphatec acquisition. Acquisition-related costs include the following:



	December 31, 2011
Professional fees	$	722
Changes in fair value of contingent consideration	350
	$	1,072

The Orphatec acquisition included contingent consideration which would obligate us to make up to $42,000 in cash milestone payments to the former Orphatec shareholders upon various development, regulatory and commercial milestones.

The initial fair value of contingent consideration was $5,086, which was recorded as a noncurrent liability. We determined the fair value of these obligations to pay additional milestone payments using various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met. This fair value measurement is based on significant inputs not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted at the rate of 4.9% for development milestones and 21% for commercial milestones, which is representative of a market participant assumption. The range of estimated milestone payments is from zero if no products gain market approval to $42,000 if all indications for up to two products gain both U.S. and European marketing approval and reach applicable sales levels.

Subsequent to the acquisition date, we have measured the contingent consideration arrangement at fair value with changes in fair value recognized in operating earnings. Changes pertaining to facts and circumstances that existed as of the acquisition date will be recognized as adjustments to goodwill. Changes in fair values reflect new information about the IPR&D assets and the passage of time. In the absence of new information, changes in fair value will only reflect the passage of time as development work progresses towards the achievement of the milestones. At December 31, 2011, the fair value of the contingent consideration for Orphatec was $5,436.

A reconciliation of upfront payments in accordance with the purchase agreement to the total purchase price is presented below:



	Orphatec
Upfront payment in accordance with agreement	$	3,050
Estimated fair value of contingent consideration	5,086
Total purchase price	$	8,136

The purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based upon their respective fair values summarized below:



	Orphatec
In-process research and development	$	8,050
Other noncurrent assets	73
Assets acquired	8,123
Goodwill	13
Net assets acquired	$	8,136

Intangible assets associated with IPR&D projects relate to the preclinical product candidate. Management estimated the acquisition-date fair value of intangible assets related to IPR&D to be $8,050. The estimated fair value was determined using the income approach, which discounts expected future cash flows to present value. We estimated the fair value using a present value discount rate of 23%, which is based on the estimated weighted-average cost of capital for companies substantially similar to that of Orphatec. This is comparable to the estimated internal rate of return for their operations and represents the rate that market participants would use to value the intangible assets. The projected cash flows from the IPR&D projects was based on key assumptions such as: estimates of revenues and operating profits related to the project considering its stage of development; the time and resources needed to complete the development and approval of the product candidate; the life of the potential commercialized product and associated risks, including the inherent difficulties and uncertainties in developing a drug compound such as obtaining marketing approval from the FDA and other regulatory agencies; and risks related to the viability of and potential alternative treatments in any future target markets.

We do not consider the acquisition of Orphatec to be a material business combination and therefore have not disclosed the pro forma results of operations.

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Appendix F
-Paragraph F4
-Subparagraph e

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1490-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1524-128463

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1392-128463

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1497-128463

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1486-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1383-128463

Prepaid Expense and Other Assets [Abstract]

Marketable Securities

12 Months Ended

Dec. 31, 2011

Marketable Securities [Abstract]

Marketable Securities

We did not hold any investments in marketable securities at December 31, 2011. The following table summarizes our marketable securities at December 31, 2010:



December 31, 2010	Amortized Cost Basis		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Other Than Temporary Impairments		Aggregate Fair Value
Commercial paper	$	65,244	$	44	$	(27	)	$	—	$	65,261
Corporate bonds	19,186		6		(8		)	—		19,184
Federal agency obligations	10,003		12		—			—		10,015
Total	$	94,433	$	62	$	(35	)	$	—	$	94,460

No realized gains or losses were recorded for the years ended December 31, 2011, 2010 and 2009. We utilize the specific identification method in computing realized gains and losses.

Prepaid Expenses and Other Assets

12 Months Ended

Dec. 31, 2011

Prepaid Expenses and Other Assets

Prepaid expenses and other current assets consist of the following:



	December 31, 2011		December 31, 2010
Prepaid taxes	$	14,128	$	7,411
Forward contract receivable	18,863		9,365
Other	17,858		10,135
	$	50,849	$	26,911



Other assets consist of the following:
	December 31, 2011		December 31, 2010
Forward contract receivable	$	6,465	$	590
Leasehold deposits	2,918		2,403
Other	3,135		1,579
	$	12,518	$	4,572

Property, Plant and Equipment, Net

12 Months Ended

Dec. 31, 2011

Property, Plant and Equipment, Net [Abstract]

Property, Plant and Equipment, Net

A summary of property, plant and equipment is as follows:



Asset	December 31, 2011			December 31, 2010
Land	$	692		$	692
Buildings and improvements	141,157			133,430
Machinery and laboratory equipment	46,021			41,986
Computer hardware and software	27,788			20,012
Furniture and office equipment	7,163			5,340
Construction-in-progress	3,638			3,831
	226,459			205,291
Less: Accumulated depreciation and amortization	(60,607		)	(43,051		)
	$	165,852		$	162,240

Depreciation and amortization of property, plant and equipment was approximately $12,236, $11,003 and $7,566 for the year ended December 31, 2011, 2010 and 2009, respectively.

At December 31, 2011 and 2010, computer software costs included in property, plant and equipment was $10,303 and $7,368, respectively. Depreciation and amortization expense for capitalized computer software costs was $3,642, $2,883 and $2,091 for the years ended December 31, 2011, 2010 and 2009, respectively.

In July 2006, we acquired ARIMF for the commercial production of Soliris and development and manufacturing of future products. Since this date, we have incurred costs related to the construction of the plant to support full-scale commercial manufacturing. We have also capitalized costs related to validation activities, including engineering runs and inventory production necessary to obtain approval of the facility from government regulators for the production of a commercially approved drug. In December 2009, we received final regulatory approval for production of commercial quantities of eculizumab by the European Commission. Accordingly, our plant was considered substantially complete and ready for its intended use. As a result of the approval, we placed the plant in service. Based on the approval, we reclassified $4,514 from property, plant and equipment to inventory. In August 2010, the U.S. Food and Drug Administration (FDA) approved ARIMF for the production of Soliris.

We recorded capitalized interest of $3,427 in the year ended December 31, 2009.

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

Intangible Assets and Goodwill

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2011

Intangible Assets, Net [Abstract]

Intangible assets and goodwill, net of accumulated amortization, are as follows:



		December 31, 2011							December 31, 2010
	Estimated Life (months)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licenses	28-96	$	23,648	$	(9,639	)	$	14,009	$	25,531	$	(8,251	)	$	17,280
Patents	90	10,517		(5,090		)	5,427		10,517		(3,651		)	6,866
Purchased technology	144	5,000		(382		)	4,618		—		—			—
Acquired IPR&D	Indefinite	67,550		—			67,550		—		—			—
Total		$	106,715	$	(15,111	)	$	91,604	$	36,048	$	(11,902	)	$	24,146
Goodwill	Indefinite	$	82,540	$	(2,901	)	$	79,639	$	22,855	$	(2,901	)	$	19,954

Amortization of our intangible assets was approximately $5,087, $4,552 and $4,663 for the years ended December 31, 2011, 2010 and 2009, respectively. Assuming no changes in the gross cost basis of intangible assets, the estimated amortization of intangible assets for the next five fiscal years is as follows:



Year
2012	$	5,615
2013	7,212
2014	7,853
2015	424
2016	417

As of December 31, 2011, we have recorded indefinite-lived intangible assets of $67,550, which consisted of $59,500 and $8,050 of purchased IPR&D from our acquisitions of Taligen and Orphatec, respectively.

The following table summarizes the changes in the carrying amount of goodwill:



Balance at December 31, 2010	$	19,954
Goodwill resulting from the Taligen acquisition	59,672
Goodwill resulting from the Orphatec acquisition	13
Balance at December 31, 2011	$	79,639

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

Derivative Instruments and Hedging Activities [Abstract]

Derivative Instruments and Hedging Activities

12 Months Ended

Dec. 31, 2011

Derivative Instruments and Hedging Activities

We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro, Japanese Yen, Swiss Franc, British Pound, Canadian dollar and Australian dollar. We manage our foreign currency transaction risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.

We enter into foreign exchange forward contracts, with durations of up to 36 months, to hedge exposures resulting from portions of our forecasted intercompany revenues that are denominated in currencies other than the U.S. dollar. The purpose of the hedges of intercompany revenue is to reduce the volatility of exchange rate fluctuations on our operating results and to increase the visibility of the foreign exchange impact on forecasted revenues. These hedges are designated as cash flow hedges upon contract inception. At December 31, 2011, we have open contracts with notional amounts totaling $520,743 that qualified for hedge accounting.

The impact on accumulated other comprehensive income (AOCI) and earnings from foreign exchange contracts that qualified as cash flow hedges, for the years ended December 31, 2011 and 2010 are as follows:



	December 31,
	2011			2010
Gain (loss) recognized in AOCI, net of tax	$	13,822		$	(2,760	)
Gain (loss) reclassified from AOCI to net product sales (Effective portion)	$	(6,558	)	$	8,778
Gain (loss) reclassified from AOCI to other income and expense (Ineffective portion)	$	(766	)	$	668

Assuming no change in foreign exchange rates from market rates at December 31, 2011, $8,046 of a gain recognized in accumulated other comprehensive income is expected to be reclassified to revenue over the next 12 months.

We enter into foreign exchange forward contracts, with durations of approximately 30 days, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. These derivative instruments do not qualify for hedge accounting; however, gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of December 31, 2011, the notional amount of foreign exchange contracts that do not qualify for hedge accounting was $171,834.

We recognized a gain of $790 and $9,443, in other income and expense, for the years ended December 31, 2011 and 2010, respectively, associated with the foreign exchange contracts not designated as hedging instruments under the guidance. These amounts were largely offset by gains or losses in monetary assets and liabilities.

The following tables summarize the fair value of outstanding derivatives at December 31, 2011 and 2010:



	December 31, 2011
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	$	14,118	Other current liabilities	$	5,889
Foreign exchange forward contracts	Other non-current assets	6,465		Other non-current liabilities	2,552
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	4,745		Other current liabilities	2,033
Total fair value of derivative instruments		$	25,328		$	10,474



	December 31, 2010
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	$	8,015	Other current liabilities	$	7,124
Foreign exchange forward contracts	Other non-current assets	590		Other non-current liabilities	3,380
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	1,350		Other current liabilities	4,724
Total fair value of derivative instruments		$	9,955		$	15,228

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80784-113994

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624181-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624177-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80748-113994

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624258-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708775-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41635-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708773-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Accrued Expenses

12 Months Ended

Dec. 31, 2011

Accrued Liabilities [Abstract]

Accrued Expenses

Accrued expenses consist of the following:



	December 31, 2011		December 31, 2010
Royalties	$	82,010	$	50,133
Payroll and employee benefits	39,453		24,034
Taxes payable	18,306		9,580
Rebates payable	21,746		4,660
Other	24,549		18,623
	$	186,064	$	107,030

See Note 11 for additional information on accrued royalties.

Debt	12 Months Ended
Debt	Dec. 31, 2011
Debt [Abstract]
Debt	Debt Convertible Notes In January 2005 we sold $150,000 principal amount of 1.375% Convertible Senior Notes due February 1, 2012 (the “1.375% Notes”). The interest rate on the notes is 1.375% per annum on the principal amount from January 25, 2005, payable semi-annually in arrears in cash on February 1 and August 1 of each year, beginning August 1, 2005. The 1.375% Notes are convertible into our common stock at an initial conversion rate of 127.1656 shares of common stock (equivalent to a conversion price of approximately $7.87 per share) per $1 principal amount of the 1.375% Notes, subject to adjustment, at any time prior to the close of business on the final maturity date of the notes. We do not have the right to redeem any of the 1.375% Notes prior to maturity. The convertible notes payable do not contain covenants related to our financial performance. In the second quarter of 2009, certain holders of the 1.375% Notes exercised conversion rights with respect to an aggregate principal amount of $87,304 resulting in the issuance of 5,644 shares of our common stock. In the second quarter of 2009, we recorded a non-cash expense of $3,395 for the fair value of the additional shares over the stated conversion rate. We reclassified $1,105 of deferred financing costs to equity in 2009 as a result of the exchange and had a remaining balance of $272 at December 31, 2009. In the first quarter of 2010, certain holders of the 1.375% Notes exercised conversion rights with respect to an aggregate principal amount of $1,000 resulting in the issuance of 63,582 shares of our common stock. In the second quarter of 2010, certain holders of the 1.375% Notes exercised conversion rights with respect to an aggregate principal amount of $5,200 resulting in the issuance of 330,629 shares of our common stock. In the second quarter of 2011, certain holders of the 1.375% Notes exercised conversion rights with respect to an aggregate principal amount of $3,000 resulting in the issuance of 190,747 shares of our common stock. At December 31, 2011, $718 of the convertible notes remains outstanding, and the fair value was approximately $6,612. In February 2012, all remaining Notes were converted for an additional 91 shares prior to maturity. Amortization expense associated with deferred financing costs for the year ended December 31, 2011, 2010 and 2009 was approximately $283, $239 and $260, respectively. Revolving Credit Facility In March 2011, we entered into a Second Amended and Restated Credit Agreement (the Amended Credit Agreement), that provides for an available $100,000 revolving credit facility through March 7, 2014, with up to a $20,000 sublimit for letters of credit, that can be used for working capital requirements, acquisitions and other general corporate purposes. With the consent of the lenders and the administrative agent and subject to satisfaction of certain conditions, we may increase the facility to $150,000. The loan is collateralized by substantially all of Alexion Pharmaceuticals, Inc.'s assets, including the pledge of the equity interests of certain direct subsidiaries and real estate located in Rhode Island, but excluding intellectual property and assets of foreign subsidiaries. We may elect that the loans under the Amended Credit Agreement bear interest at a rate per annum equal to (i) LIBOR plus 1.75% to 2.25% depending on the ratio of our cash to liabilities (as calculated in accordance with the agreement), or (ii) a Base Rate equal to the higher of the (A) Prime Rate then in effect, (B) Federal Funds Rate then in effect plus 0.50%, and (C) Eurodollar Rate then in effect plus 1.00%, plus 0.75% to 1.25% depending on the ratio of our cash to liabilities (as calculated in accordance with the agreement). Interest is payable quarterly for Base Rate loans and, in the case of LIBOR-based loans, at the end of the applicable interest period, with the principal due on March 7, 2014, the maturity date. The Amended Credit Agreement requires us to comply with certain financial covenants on a quarterly basis. Further, the Amended Credit Agreement includes negative covenants, subject to exceptions, restricting or limiting our ability and the ability of our subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, and enter into transactions with affiliates. The Amended Credit Agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the interest rate would increase and the administrative agent would be entitled to take various actions, including the acceleration of amounts due under the loan. As of December 31, 2011, we had no outstanding amounts under the revolving credit facility other than open letters of credit of $3,754. Our borrowing availability was approximately $96,000 at December 31, 2011. In February 2012, this credit facility was terminated and replaced with a new five-year, $440,000 credit facility (see Note 18).

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Commitments and Contingencies Disclosure [Abstract]

Capital Leases

12 Months Ended

Dec. 31, 2011

Leases, Capital [Abstract]

Capital Leases

We lease office equipment and software licenses under capital lease agreements expiring in 2014. The assets and liabilities under capital leases are recorded at the lesser of the present value of the minimum lease payments or the fair value of the asset. The assets are amortized over the lower of their related lease terms or their estimated useful lives. Amortization of assets under capital lease is included in depreciation expense. The cost of equipment under capital lease was $2,692 and $2,642 and accumulated amortization was $1,524 and $958, at December 31, 2011 and 2010, respectively. The weighted-average interest rate on the capital leases is approximately 4.04%.

Minimum future lease payments under capital lease as of December 31, 2011 are:



Year
2012	$	779
2013	191
2014	3
	973
Less: Amount representing interest	64
Present value of minimum lease payments	$	909

Commitments and Contingencies

12 Months Ended

Dec. 31, 2011

Commitments and Contingencies

Commitments

We have supply agreements with Lonza relating to the manufacture of eculizumab, which requires payments to Lonza at the inception of contract and as product is manufactured. On an ongoing basis, we evaluate our plans for future levels of manufacturing by Lonza, which depends upon our commercial requirements, the progress of our clinical development programs and the production levels of ARIMF.

We have various agreements with Lonza, with remaining total commitments of approximately $136,000 through 2018. Such commitments may be canceled only in limited circumstances. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of Soliris manufactured at ARIMF.

Contingent Liabilities

On January 26, 2011, Novartis Vaccines & Diagnostics, Inc. (Novartis) filed a civil action against us and other biopharmaceutical companies in the U.S. District Court for the District of Delaware. Novartis claims willful infringement by us of U.S. Patent No. 5,688,688. Novartis seeks, among other things, monetary damages. If it is finally determined that we infringe the Novartis patent, we may be required to pay royalties to Novartis on sales of Soliris regarding certain manufacturing technology. Although we do not believe that the manufacture of Soliris infringes a valid patent claim owned by Novartis, we cannot guarantee that we will be successful in defending against such action. Given the early stages of this litigation, management does not currently believe a loss related to this matter is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated.

In addition to the Novartis claim, other third parties may claim that the manufacture, use or sale of Soliris or other drugs under development infringes patents owned or granted to such third parties. We are aware of broad patents owned by others relating to the manufacture, use and sale of recombinant humanized antibodies, recombinant human antibodies, and recombinant human single chain antibodies. Soliris and many of our product candidates are genetically engineered antibodies, including recombinant humanized antibodies, recombinant human antibodies, or recombinant human single chain antibodies. In addition to the action described above, we have received notices from the owners of some of these patents claiming that their patents may be infringed by the development, manufacture or sale of Soliris or some of our drug candidates. We are also aware of other patents owned by third parties that might be claimed by such third parties to be infringed by the development and commercialization of Soliris and some of our drug candidates. In respect to some of these patents, we have obtained licenses, or expect to obtain licenses. We estimate our obligations for probable contingent liabilities based on our assessment of estimated royalties potentially owed to other third parties. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our business. However, the amount of such loss or a range of loss, if any, beyond amounts currently accrued cannot be reasonably estimated.

At December 31, 2011 and 2010, we have recorded $82,010 and $50,133 respectively, in accrued expenses for royalties. Our cost of sales for the years ended December 31, 2011, 2010 and 2009 includes amounts recorded for both changes in contingent liabilities described above and for existing royalty agreements.

Operating Leases

As of December 31, 2011, we lease our headquarters and primary research and development facilities in Cheshire, Connecticut. The lease is set to expire in September 2020. Monthly fixed rent started at approximately $162, increasing to approximately $232 over the term of this lease. We also lease space for our regional executive and sales offices in Lausanne, Switzerland, as well as in other countries to support our operations as a global organization.

Aggregate lease expense for our facilities was $10,424, $6,980 and $6,817 for the years ended December 31, 2011, 2010 and 2009, respectively. Lease expense is being recorded on a straight-line basis over the applicable lease terms.

Aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases (including facilities and equipment) as of December 31, 2011 are:



Year
2012	$	12,089
2013	10,146
2014	7,288
2015	4,652
2016	4,320
Thereafter	11,259

License and Research and Development Agreements

We have entered into a number of license, research and development and manufacturing development agreements since our inception. These agreements have been made with various research institutions, universities, contractors, collaborators, and government agencies in order to advance and obtain technologies and services related to our business.

License agreements generally provide for us to pay an initial fee followed by annual minimum royalty payments. Additionally, certain agreements call for future payments upon the attainment of agreed upon milestones, such as, but not limited to, Investigational New Drug (IND) application or approval of Biologics License Application. These agreements require minimum royalty payments based on sales of products developed from the applicable technologies, if any.

Clinical and manufacturing development agreements generally provide for us to fund manufacturing development and on-going clinical trials. Clinical trial and development agreements include contract services and outside contractor services including contracted clinical site services related to patient enrolment for our clinical trials. Manufacturing development agreements include clinical manufacturing and manufacturing development and scale-up. We have executed a large-scale product supply agreement with Lonza Sales AG for the long-term commercial manufacture of Soliris.

In order to maintain our rights under these agreements, we may be required to provide a minimum level of funding or support. Accordingly, we recognize the expense and related obligation related to these arrangements over the period of performance.

The minimum fixed payments (assuming non-termination of the above agreements) as of December 31, 2011, for each of the next five years are as follows:



Year	License Agreements		Clinical and Manufacturing Development Agreements
2012	$	253	$	40,200
2013	203		14,990
2014	203		15,000
2015	203		15,520
2016	203		16,070
	$	1,065	$	101,780

Income Taxes

12 Months Ended

Dec. 31, 2011

Income Tax Disclosure [Abstract]

Income Taxes

The income tax provision (benefit) is based on income before income taxes as follows:



	2011		2010		2009
U.S.	$	158,472	$	108,226	$	86,803
Non-U.S.	71,196		40,785		(3,489		)
	$	229,668	$	149,011	$	83,314

The components of the income tax provision (benefit) are as follows:



	2011			2010			2009
Income Tax Provision (Benefit)
Domestic
Current	$	(904	)	$	5,013		$	(7,742	)
Deferred	45,463			40,569			(207,604		)
	44,559			45,582			(215,346		)
Foreign
Current	13,191			9,728			4,601
Deferred	(3,397		)	(3,329		)	(1,107		)
	9,794			6,399			3,494
Total
Current	12,287			14,741			(3,141		)
Deferred	42,066			37,240			(208,711		)
	$	54,353		$	51,981		$	(211,852	)

We reversed the valuation allowance against certain non-U.S. deferred tax assets in the second quarter of 2010 where realization of those assets was more likely than not. In the fourth quarter of 2009, we also reversed the valuation allowance recorded against a substantial portion of our deferred tax assets in the United States. We continue to maintain a valuation allowance against certain other deferred tax assets where the realization is not certain. We periodically evaluate the likelihood of the realization of deferred tax assets and reduce the carrying amount of these deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized.

Due to the amount of our NOL’s and credit carryforwards, we do not anticipate paying substantial U.S. federal income taxes in the near future. We are currently paying cash taxes in various U.S. states and foreign jurisdictions where we have operations and have utilized all of our net operating losses.

At December 31, 2011, we have federal and state net operating loss carryforwards of $464,918 and $109,095, respectively. These NOL's are inclusive of federal and state net operating losses of approximately $36,500 and $28,300, respectively, from our acquisition of Taligen. Included in the NOL’s are federal and state NOL’s of $315,689 and $49,911, respectively, attributable to excess tax benefits from the exercise of non-qualified stock options. The tax benefits attributable to these NOL’s will be credited directly to additional paid in capital when utilized to offset taxes payable. Our NOL’s expire between 2012 and 2031. We also have federal and state income tax credit carryforwards of approximately $72,278 and $1,361, respectively. These income tax credits expire between 2012 and 2031. Additionally, included in these income tax credit carryforwards are federal income tax credit carryforwards of $8,473 attributable to excess tax benefits from the exercise of non-qualified stock options.

Certain stock option exercises resulted in tax deductions in excess of previously recorded benefits based on the option value at the time of grant. Although these additional tax benefits or “windfalls” are reflected in net operating loss carryforwards, pursuant to authoritative guidance, the additional tax benefit associated with the windfall is not recognized until the deduction reduces regular taxes payable. Accordingly, since the tax benefit does not reduce our current taxes payable due to net operating loss carryforwards, these “windfall” tax benefits are not reflected in our net operating losses and credit carryforward in deferred tax assets for all periods presented.

We were granted an incentive tax holiday in the Canton of Vaud in Switzerland effective January 1, 2010, with a final expiration date in 2019. The tax holiday will exempt the Company from most local corporate income taxes in Switzerland through the end of 2014 and is expected to be renewed for an additional 5 years.

The Tax Reform Act of 1986 contains certain provisions that can limit a taxpayer's ability to utilize net operating loss and tax credit carryforwards in any given year resulting from cumulative changes in ownership interests in excess of 50 percent over a three-year period. We have determined that these limiting provisions were triggered during a prior year. However, we believe that such limitation is not expected to result in the expiration or loss of any significant amount of our federal NOL’s and income tax credit carryforwards.

In September 2011, we completed our assessment of the impact the election to claim federal foreign tax credits and the federal orphan drug credits would have on our historical tax returns. Based on this assessment, management elected to claim both the foreign tax credit for the tax year ended December 31, 2010 and orphan drug credit for the tax years ended December 31, 2010 and 2009. The net federal income tax benefit recorded during 2011 as a result of the election to claim the federal foreign tax credit for 2010 and the federal orphan drug credit for 2010 and 2009 was approximately $15,400.

The provision (benefit) for income taxes differs from the U.S. federal statutory tax rate. The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate is as follows:



	December 31,
	2011		2010		2009
U.S. federal statutory tax rate	35.0	%	35.0	%	35.0	%
State and local income taxes	2.5	%	2.5	%	0.8	%
Foreign income tax rate differential	-9.4	%	-4.9	%	5.0	%
Income tax credits	-14.1	%	-1.0	%	-12.1	%
Foreign income subject to U.S. taxation	3.4	%	1.6	%	0.2	%
Stock option compensation	1.0	%	1.3	%	2.0	%
Non-deductible acquisition related costs	0.3	%	—	%	—	%
Other nondeductible and permanent differences	5.0	%	1.1	%	0.3	%
Provision (benefit) attributable to valuation allowances	—	%	-0.7	%	-285.5	%
Effective income tax rate	23.7	%	34.9	%	-254.3	%

Provisions have been made for deferred taxes based on the differences between the basis of the assets and liabilities for financial statement purposes and the basis of the assets and liabilities for tax purposes using currently enacted tax rates and regulations that will be in effect when the differences are expected to be recovered or settled. The components of the deferred tax assets and liabilities, which exclude "windfall" tax benefits, are as follows:



	December 31,			December 31,
	2011			2010
Deferred tax assets:
Net operating losses	$	54,421		$	126,111
Income tax credits	64,689			35,293
Stock compensation	22,459			16,814
Accruals and allowances	40,110			28,728
Intangible assets	—			8,013
	181,679			214,959
Valuation allowance	(3,074		)	(2,470		)
Total deferred tax assets	178,605			212,489
Deferred tax liabilities:
Depreciable assets	(40,760		)	(37,805		)
Intangible assets	(14,847		)	—
Unrealized gains	(860		)	(471		)
Total deferred tax liabilities	(56,467		)	(38,276		)
Net deferred tax asset	$	122,138		$	174,213

We follow authoritative guidance regarding accounting for uncertainty in income taxes, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

The beginning and ending amounts of unrecognized tax benefits reconciles as follows:



	2011			2010			2009
Beginning of period balance	$	8,658		$	7,305		$	9,569
Increases for tax positions taken during a prior period	186			184			59
Decreases for tax positions taken during a prior period	(689		)	(22		)	(3,018		)
Increases for tax positions taken during the current period	1,692			1,191			695
Reduction as a result of a lapse of statute of limitations	—			—			—
Decreases for tax positions related to settlements	(74		)	—			—
	$	9,773		$	8,658		$	7,305

We recognize the interest accrued and the penalties related to unrecognized tax benefits as a component of tax expense. The total amount of accrued interest and penalties and the tax expense as of December 31, 2011 is $442. Unless related to excess tax benefits from stock options, all of our unrecognized tax benefits, if recognized, would have a favorable impact on the effective tax rate.

We file federal and state income tax returns in the U.S. and in numerous foreign jurisdictions. The U.S. and foreign jurisdictions have statute of limitations ranging from 3 to 5 years. However, the statute of limitations could be extended due to our NOL carryforward position in a number of our jurisdictions. The tax authorities generally have the ability to review income tax returns for periods where the statute of limitation has previously expired and can subsequently adjust the NOL carryforward or tax credit amounts. Accordingly, we do not expect to reverse any significant portion of the unrecognized tax benefits within the next year.

The Internal Revenue Service (IRS) commenced an examination of our U.S. income tax returns for 2008 and 2009 during the second quarter 2011 that is anticipated to be completed within the next twelve months. As a result of this audit, it is possible that the amount of the liability for unrecognized tax benefits could change over the next twelve months. The impact to our unrecognized tax benefits is difficult to determine based on the preliminary stage of the audit. As of December 31, 2011, we have not been notified of any significant proposed adjustments by the IRS.

We have not provided US income taxes on undistributed earnings of our non-US subsidiaries as these earnings are intended to be either permanently reinvested or subject to a tax free liquidation and not give rise to significant incremental US taxes. It is not practical to estimate the amount of additional taxes which might be payable on our undistributed earnings due to a variety of factors, including the timing, extent and nature of any repatriation.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Options and Restricted Stock

12 Months Ended

Dec. 31, 2011

Stock Options and Restricted Stock

At December 31, 2011, we have one stock option plan, the 2004 Incentive Plan (“2004 Plan”). Under the 2004 Plan, restricted stock and restricted stock units (collectively referred to as Restricted Stock), incentive and non-qualified stock options, and other stock-related awards, may be granted for up to a maximum of 29,874 shares to our directors, officers, key employees and consultants. Stock options granted under all Plans have a maximum contractual term of ten years from the date of grant, have an exercise price not less than the fair value of the stock on the grant date and generally vest over four years.

The following table summarizes the components of share-based compensation expense in the consolidated statements of operations:



	December 31,
	2011		2010		2009
Cost of sales	$	2,375	$	1,266	$	—
Research and development	9,759		7,878		9,049
Selling, general and administrative	32,629		23,194		19,682
Total share-based compensation expense	$	44,763	$	32,338	$	28,731

The following table summarizes the share-based compensation capitalized to inventory and fixed assets:



	December 31,
	2011		2010		2009
Share-based compensation expense capitalized to inventory	$	2,954	$	2,785	$	1,403
Share-based compensation expense capitalized to fixed assets	$	—	$	—	$	970

The weighted average fair value at the date of grant for options granted during the years ended December 31, 2011, 2010 and 2009 is $15.46, $8.50 and $7.48 per option, respectively.

As of December 31, 2011, there was $78,817 of total unrecognized share-based compensation expense related to non-vested share-based compensation arrangements granted under the Plan. The expense is expected to be recognized over a weighted-average period of 2.69 years.

A summary of the status of our stock option plans at December 31, 2011, and changes during the year then ended is presented in the table and narrative below:



	Number of shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2010	12,228		$	15.27
Granted	2,556		45.38
Exercised	(2,744	)	13.05
Forfeited and cancelled	(274	)	36.20
Outstanding at December 31, 2011	11,766		$	21.83	6.76	$	584,395
Vested and unvested expected to vest at December 31, 2011	11,506		$	21.61	6.73	$	574,008
Exercisable at December 31, 2011	7,246		$	15.04	5.73	$	409,130

Total intrinsic value of stock options exercised during the years ended December 31, 2011, 2010 and 2009 was $114,712, $64,656 and $33,335, respectively. We primarily utilize newly issued shares to satisfy the exercise of stock options. The total fair value of shares vested during the years ended December 31, 2009, 2010 and 2009 was $23,485, $20,039 and $20,734, respectively.

The fair value of options at the date of grant was estimated using the Black-Scholes model with the following ranges of weighted average assumptions:



	December 31,	December 31,	December 31,
	2011	2010	2009
Expected life in years	3.53 - 5.84	3.55 - 5.90	3.67 - 6.24
Interest rate	0.61% - 1.89%	0.84% - 2.16%	1.41% - 2.19%
Volatility	37.43% - 40.14%	40.70% - 42.48%	40.30% - 48.03%
Dividend yield	—	—	—

The expected stock price volatility rates are based on historical volatilities of our common stock. The risk-free interest rates are based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The average expected life represents the weighted average period of time that options granted are expected to be outstanding. We have evaluated three distinct employee groups in determining the expected life assumptions, and we estimate the expected life of stock options based on historical experience of exercises, cancellations and forfeitures of our stock options.

A summary of the status of our nonvested Restricted Stock and changes during the period then ended is as follows:



	December 31,
	2011
Nonvested Restricted Stock, beginning of period	2,122
Shares issued	807
Shares cancelled	(138	)
Shares vesting	(732	)
Nonvested Restricted Stock, end of period	2,059
Weighted average grant date fair value	$44.25

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Common and Preferred Stock	12 Months Ended
Common and Preferred Stock	Dec. 31, 2011
Common and Preferred Stock [Abstract]
Common and Preferred Stock	Common and Preferred Stock Preferred Stock In February 1997, our Board of Directors declared a dividend of one preferred stock purchase right for each outstanding share of Common Stock (including all future issuances of Common Stock). Under certain conditions, each right may be exercised to purchase one hundredth of a share of a new series of preferred stock at an exercise price of $75.00, subject to adjustment (see below). The rights may be exercised only after a public announcement that a party acquired 20 percent or more of our Common Stock or after commencement or public announcement to make a tender offer for 20 percent or more of our Common Stock. The rights, which do not have voting rights, expire on March 6, 2017, and may be redeemed by us at a price of $0.01 per right at any time prior to their expiration or the acquisition of 20 percent or more of our stock. The preferred stock purchasable upon exercise of the rights will have a minimum preferential dividend of $10.00 per year, but will be entitled to receive, in the aggregate, a dividend of 100 times the dividend declared on a share of Common Stock. In the event of liquidation, the holders of the shares of preferred stock will be entitled to receive a minimum liquidation payment of $100 per share, but will be entitled to receive an aggregate liquidation payment equal to 100 times the payment to be made per share of Common Stock. On February 23, 2007, our Board of Directors amended the purchase price under the preferred stock purchase rights. Further, as a result of the two-for-one stock split of the Company's outstanding shares of Common Stock effected on August 22, 2008, the number of shares of preferred stock purchasable upon proper exercise of each preferred stock purchase right automatically adjusted from one hundredth of a share of preferred stock to two hundredths of a share of preferred stock. Therefore, the purchase price, for each two hundredths of a share of preferred stock to be issued upon the exercise of each preferred stock purchase right is $300.00. Except for the increase in the purchase price, the terms and conditions of the rights remain unchanged. In the event that we are acquired in a merger, other business combination transaction, or 50 percent or more of our assets, cash flow, or earning power are sold, proper provision shall be made so that each holder of a right shall have the right to receive, upon exercise thereof at the then current exercise price, that number of shares of Common Stock of the surviving company which at the time of such transaction would have a market value of two times the exercise price of the right.

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 02
-Paragraph 29

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 150
-Paragraph 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6403732&loc=d3e21300-112643

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802392&loc=d3e177068-122764

Fair Value Measurement

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Abstract]

Fair Value Measurement

Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2011 and 2010, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.



		Fair Value Measurement at December 31, 2011
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	428,431	$	—	$	428,431	$	—
Other current assets	Foreign exchange forward contracts	$	18,863	$	—	$	18,863	$	—
Other assets	Foreign exchange forward contracts	$	6,465	$	—	$	6,465	$	—
Other current liabilities	Foreign exchange forward contracts	$	7,922	$	—	$	7,922	$	—
Other liabilities	Foreign exchange forward contracts	$	2,552	$	—	$	2,552	$	—
Contingent consideration	Acquisition-related contingent consideration	$	18,120	$	—	$	—	$	18,120



		Fair Value Measurement at December 31, 2010
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	186,565	$	—	$	186,565	$	—
Marketable securities	Commercial paper	$	65,261	$	—	$	65,261	$	—
Marketable securities	U.S. Corporate bonds	$	19,184	$	—	$	19,184	$	—
Marketable securities	Federal agency obligations	$	10,015	$	—	$	10,015	$	—
Other current assets	Foreign exchange forward contracts	$	9,365	$	—	$	9,365	$	—
Other assets	Foreign exchange forward contracts	$	590	$	—	$	590	$	—
Other current liabilities	Foreign exchange forward contracts	$	11,848	$	—	$	11,848	$	—
Other liabilities	Foreign exchange forward contracts	$	3,380	$	—	$	3,380	$	—

The following table represents a roll-forward of the fair value of Level 3 instruments, comprised solely of acquisition-related contingent consideration:



	December 31, 2011
Balance at beginning of period	$	—
Amounts acquired or issued	(16,720		)
Change in fair value	(1,400		)
Balance at end of period	$	(18,120	)

Valuation Techniques

Items classified as Level 2 within the valuation hierarchy, consisting of an institutional money market fund held at a multinational financial institution, corporate and federal agency bonds and commercial paper are valued based upon pricing of securities with similar investment characteristics and holdings. Our derivative assets and liabilities include foreign exchange derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk and our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy. Items classified as Level 3 within the valuation hierarchy, consisting of contingent consideration liabilities related to the Taligen and Orphatec acquisitions, were valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.

As of December 31, 2011, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plans

12 Months Ended

Dec. 31, 2011

Employee Benefit Plans

Defined Contribution Plan

We have one qualified 401(k) plans covering all eligible employees. Under the plan, employees may contribute up to the statutory allowable amount for any calendar year. We make matching contributions equal to:


•	$1.00 for each dollar contributed up to the first 4% of an individual’s base salary and incentive cash bonus; and


•	$0.50 for each dollar contributed of the next 2% of such compensation.

For the years ended December 31, 2011, 2010 and 2009, we recorded matching contributions of approximately $2,882, $1,893 and $1,552, respectively.

Defined Benefit Plan

We maintain defined benefit plans for employees outside the United States, including a retirement benefit plan required by local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments.

The following table sets forth the funded status and the amounts recognized for defined benefit plans:



	December 31,
	2011			2010
Change in benefit obligation:
Projected benefit obligation, beginning of year	$	13,358		$	5,655
Prior service cost	—			76
Service cost	4,540			2,240
Interest cost	449			266
Change in assumptions	555			1,055
Recognized actuarial net loss	708			1,017
Foreign currency exchange rate changes	(214		)	929
Transfers into plan	(387		)	2,120
Projected benefit obligation, end of year	$	19,009		$	13,358
Accumulated benefit obligation, end of year	$	15,170		$	11,110



	December 31,
	2011			2010
Change in plan assets:
Fair value of plan assets, beginning of year	$	9,542		$	4,737
Return on plan assets	197			108
Employer contributions	1,706			1,646
Plan participants' contributions	1,056			666
Foreign currency exchange rate changes	744			945
Transfers into plan	(387		)	1,440
Fair value of plan assets, end of year	$	12,858		$	9,542
Funded status at end of year	$	(6,151	)	$	(3,816	)

The following table provides information about the fair value of the plan assets per asset category:



	December 31, 2011				December 31, 2010
	Fair Value (Level 2)		as % of total plan assets		Fair Value (Level 2)		as % of total plan assets
Cash and cash equivalents	$	1,169	9	%	$	921	10	%
Equity security funds	3,661		28	%	2,473		26	%
Debt security funds	6,502		51	%	4,934		52	%
Real estate funds	1,526		12	%	1,214		12	%
	$	12,858	100	%	$	9,542	100	%

At December 31, 2011, we have recorded a liability of $6,151 in other non-current liabilities and a charge to accumulated other comprehensive income, net of tax of $4,183 related to an additional minimum liability.

The following table provides the weighted average assumptions used to calculate net periodic benefit cost and the actuarial present value of projected benefit obligations:



	December 31,
	2011		2010
Weighted average assumptions:
Discount rate	2.4	%	2.7	%
Long term rate of return on assets	4.0	%	4.0	%
Rate of compensation increase	1.0	%	1.5	%

The expected long-term rate of return on plan assets represents a weighted average of expected returns per asset category.

The rate of return considers historical and estimated future risk free rates of return as well as risk premiums for the relevant investment categories.

The components of net periodic benefit cost are as follows:



	December 31,
	2011			2010
Service cost	$	4,540		$	2,240
Interest cost	449			266
Expected return on plan assets	(473		)	(265		)
Employee contributions	(1,056		)	(666		)
Amortization of prior service costs	9			8
Amortization and deferral of actuarial gain (loss)	305			35
Total net periodic benefit cost	$	3,774		$	1,618

The investment objective of the collective trust is to maximize the overall return from investment income and capital appreciation consistent with the preservation of capital considering investment strategies and asset allocation limits as determined by pension law. The targeted allocation for these funds (if any) is as follows:



	Target Allocation Ranges in %
Cash and notes receivable issued by banks or insurance companies	0-10%
Equity securities	8-20%
Debt securities	38-76%
Real estate	10-20%

Other changes in plan assets and benefit obligations recognized in other comprehensive income (OCI) for the year ended December 31, 2011 are as follows:



Amount included in OCI-beginning of year	$	(3,018	)
Prior service cost	—
Net gain (loss) arising during the period	(639		)
Change in assumptions	(561		)
Amortization of net gain (loss)	242
Plan assets losses	(279		)
Taxes	72
Amount included in OCI-end of year	$	(4,183	)

We estimate that we will pay employer contributions of approximately $2,560 in 2012. The expected future cash flows to be paid in respect of the pension plans as of December 31 were as follows:



Estimated future benefit payments
2012	$	937
2013	994
2014	977
2015	1,010
2016	916
2017 to 2021	5,137

The entire disclosure for pension and other postretirement benefits.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Segment Information

12 Months Ended

Dec. 31, 2011

Segment Reporting [Abstract]

Segment Information

We operate as one business segment, which is the business of focusing on serving patients with severe and ultra-rare disorders though the innovation, development and commercialization of life-transforming therapeutic products and therefore, our chief operating decision-maker manages the operations of our Company as a single operating segment.

Revenues and tangible long-lived assets by significant geographic region are as follows:



	December 31,
Revenues:	2011		2010		2009
United States	$	263,387	$	205,792	$	159,829
Europe	340,812		275,608		215,763
Asia Pacific (primarily Japan)	115,377		22,188		—
Other	63,855		37,369		11,208
	$	783,431	$	540,957	$	386,800

	December 31,
Long-lived assets (1):	2011		2010
United States	$	157,473	$	154,227
Europe	6,288		6,557
Other	2,091		1,456
	$	165,852	$	162,240


(1)	Long-lived assets consist of property, plant and equipment.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Quarterly Financial Information Disclosure [Abstract]

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2011
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 7, 2012, we acquired Enobia Pharma Corp. (Enobia), a privately held clinical-stage biotechnology company based in Montreal, Canada and Cambridge, Massachusetts, in a transaction expected to be accounted for as a business combination. The acquisition was intended to broaden our objective to develop and deliver therapies for patients with ultra-rare, severe, and life-threatening disorders. Enobia's lead product candidate ENB-0040 (asfotase alfa), is a human recombinant targeted alkaline phosphatase enzyme-replacement therapy for patients suffering with hypophosphatasia (HPP), an ultra-rare, life-threatening, genetic metabolic disease for which there are no approved treatments. We made an upfront cash payment of $610,000, subject to purchase price adjustments, for 100% of Enobia's capital stock. Additional contingent payments would be earned upon reaching various regulatory and sales milestones. If all such regulatory and sales milestones were achieved, the total additional payments would be $470,000. We financed the acquisition through available cash and proceeds from our new credit facility as noted below. As of December 31, 2011, we incurred $2,039 of acquisition-related costs comprised primarily of professional fees. In conjunction with our acquisition of Enobia, we entered into a five-year, $440,000 credit facility with a syndication of banks. The credit facility consists of a $240,000 term loan payable in equal quarterly installments of $12,000 starting June 30, 2012 and a $200,000 revolving line of credit. The credit facility bears interest at a per annum rate of LIBOR plus 1.25% to 2.00% depending on certain leverage ratios (as calculated in accordance with the agreement). We borrowed $80,000 on the revolving line of credit in connection with the Enobia acquisition.

Quarterly Financial Information (unaudited)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Information (unaudited)

The following condensed quarterly financial information is for the years ended December 31, 2011 and 2010:



	Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2011:
Revenues	$	166,126	$	185,699	$	204,047	$	227,559
Cost of sales	19,228		21,745		23,369		28,798
Operating expenses (1)	106,665		114,930		114,479		123,391
Operating income	40,233		49,024		66,199		75,370
Net income	$	26,830	$	34,745	$	65,570	$	48,170
Earnings per common share (2)
Basic	$	0.15	$	0.19	$	0.36	$	0.26
Diluted	$	0.14	$	0.18	$	0.34	$	0.25

	March 31,		June 30,		September 30,		December 31,
2010:
Revenues	$	117,578	$	125,834	$	141,569	$	155,976
Cost of sales	13,999		13,721		16,495		20,222
Operating expenses	73,009		79,788		82,361		90,724
Operating income	30,570		32,325		42,713		45,030
Net income	$	20,934	$	21,773	$	27,873	$	26,450
Earnings per common share (2)
Basic	$	0.12	$	0.12	$	0.16	$	0.15
Diluted	$	0.11	$	0.12	$	0.15	$	0.14

(1) Included within operating expenses for the first quarter 2011 are acquisition-related costs of $9,928 associated with the Taligen and Orphatec acquisitions.

(2) On May 20, 2011, we effected a two-for-one stock split, paid in the form of a 100% stock dividend. Stockholders of record at the close of trading on May 2, 2011 were issued one additional share of common stock for each share owned by such shareholder. All per share data presented in the accompanying table has been retroactively restated to reflect the stock split.

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

Business Overview and Summary of Significant Accounting Policies [Abstract]

Business Overview and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2011

Basis of Presentation and Principles of Consolidation

We have reclassified certain disclosure amounts for the prior period to conform to the current year presentation.

Dividend Policy

Critical Accounting Estimates

The most significant areas involving estimates, judgments and assumptions used in the preparation of our consolidated financial statements are as follows:


•	Revenue recognition;


•	Contingent liabilities;


•	Inventories;


•	Research and development expenses;


•	Share-based compensation;


•	Valuation of goodwill, acquired intangible assets and in-process research and development (IPR&D);


•	Valuation of contingent consideration; and


•	Income taxes.

Foreign Currency Translation

Cash and Cash Equivalents

Cash and cash equivalents are stated at cost plus accrued interest, which approximates fair value, and include short-term highly liquid investments with original maturities of three months or less.

Fair Value of Financial Instruments

Marketable Securities

Accounts Receivable

Inventories

Capitalization of Inventory Costs

Inventory Write-Offs

Inventories are stated at the lower of cost or estimated realizable value. We determine the cost of inventory using the weighted-average cost method.

Derivative Instruments

Prepaid Manufacturing Costs

Property, Plant and Equipment

Property, plant and equipment are stated at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. We estimate economic lives as follows:


•	Building and improvements—five to thirty years


•	Machinery and laboratory equipment—three to twenty years


•	Computer hardware and software—two to five years


•	Furniture and office equipment—three to seven years

Construction-in-progress reflects amounts incurred for property, plant, or equipment construction or improvements that have not been placed in service.

Intangible Assets

Goodwill

Impairment of Long-Lived Assets

Contingent liabilities

Contingent Consideration

Revenue Recognition

Research and Development Expenses

Share-Based Compensation

Earnings Per Common Share

Income Taxes

Comprehensive Income (Loss)

Business Overview and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2011

Business Overview and Summary of Significant Accounting Policies [Abstract]

Schedule of Inventories

The components of inventory are as follows:



	December 31,
	2011		2010
Raw materials	$	9,677	$	4,835
Work-in-process	37,000		37,312
Finished goods	34,709		20,018
	$	81,386	$	62,165

Schedule of the Calculation of Basic and Diluted EPS

The following table summarizes the calculation of basic and diluted EPS for years ended December 31, 2011, 2010 and 2009:



	December 31,
	2011		2010		2009
Net income used for basic calculation	$	175,315	$	97,030	$	295,166
Weighted-average effect of dilutive securities:
Interest expense and debt financing cost amortization, net of tax, related to our 1.375% convertible senior notes	26		72		298
Net income used for diluted calculation	$	175,341	$	97,102	$	295,464
Shares used in computing earnings per common share—basic	183,220		178,542		170,652
Weighted-average effect of dilutive securities:
Shares issuable upon the assumed conversion of our 1.375% convertible senior notes	198		766		4,918
Stock awards	8,388		6,766		5,594
Dilutive potential common shares	8,586		7,532		10,512
Shares used in computing earnings per common share—diluted	191,806		186,074		181,164
Earnings per common share:
Basic	$	0.96	$	0.54	$	1.73
Diluted	$	0.91	$	0.52	$	1.63

Schedule of Potentially Dilutive Shares Excluded from the Calculation of EPS

The following table represents the potentially dilutive shares excluded from the calculation of EPS for the years ended December 31, 2011, 2010 and 2009 because their effect is anti-dilutive:



	December 31,
	2011	2010	2009
Potentially dilutive securities:
Options to purchase common stock	1,905	2,468	4,480
Unvested restricted stock and restricted stock units	15	6	14
	1,920	2,474	4,494

Schedule of Comprehensive Income (Loss)

A summary of accumulated other comprehensive income (loss) is summarized as follows:



	Pension Liability			Net Unrealized Gain(Loss) from Marketable Securities			Net Unrealized Gain(Loss) From Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income(Loss)
Balance December 31, 2009	$	(1,120	)	$	22		$	259		$	(1,103	)	$	(1,942	)
Period Change	(1,898		)	(12		)	(2,760		)	(528		)	(5,198		)
Balance December 31, 2010	$	(3,018	)	$	10		$	(2,501	)	$	(1,631	)	$	(7,140	)
Period Change	(1,165		)	(10		)	13,822			(1,328		)	11,319
Balance December 31, 2011	$	(4,183	)	$	—		$	11,321		$	(2,959	)	$	4,179

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2011

Taligen Therapeutics Inc Member

Schedule of Acquisition Related Costs



	December 31, 2011
Separately-identifiable employee costs	$	6,597
Professional fees	2,728
Changes in fair value of contingent consideration	1,050
	$	10,375

Reconciliation Of Upfront Payments To Total Purchase Price



	Taligen
Upfront payment in accordance with agreement	$	111,773
Separately-identifiable employee costs	(6,259		)
Total consideration transferred	$	105,514
Estimated fair value of contingent consideration	11,634
Total purchase price	$	117,148

Schedule of Purchase Price Allocation



	Taligen
Cash and cash equivalents	$	2,678
Purchased technology	5,000
In-process research and development	59,500
Other assets	555
Assets acquired	67,733
Deferred tax liability (net)	(9,173		)
Other liabilities assumed	(1,084		)
Liabilities assumed	(10,257		)
Goodwill	59,672
Net assets acquired	$	117,148

Business Acquisition, Pro Forma Information



	December 31,
	2011		2010
Revenues	$	783,431	$	541,413
Net income	174,209		84,662
Earnings per common share
Basic	$	0.95	$	0.47
Diluted	$	0.91	$	0.45

Orphatec Pharmaceuticals Gmbh Member

Schedule of Acquisition Related Costs



	December 31, 2011
Professional fees	$	722
Changes in fair value of contingent consideration	350
	$	1,072

Reconciliation Of Upfront Payments To Total Purchase Price



	Orphatec
Upfront payment in accordance with agreement	$	3,050
Estimated fair value of contingent consideration	5,086
Total purchase price	$	8,136

Schedule of Purchase Price Allocation



	Orphatec
In-process research and development	$	8,050
Other noncurrent assets	73
Assets acquired	8,123
Goodwill	13
Net assets acquired	$	8,136

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

Schedule of Marketable Securities

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2010

Marketable Securities [Abstract]

The following table summarizes our marketable securities at December 31, 2010:



December 31, 2010	Amortized Cost Basis		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Other Than Temporary Impairments		Aggregate Fair Value
Commercial paper	$	65,244	$	44	$	(27	)	$	—	$	65,261
Corporate bonds	19,186		6		(8		)	—		19,184
Federal agency obligations	10,003		12		—			—		10,015
Total	$	94,433	$	62	$	(35	)	$	—	$	94,460

Tabular disclosure of available-for-sale securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Prepaid Expense and Other Assets [Abstract]

Prepaid Expenses and Other Assets (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:



	December 31, 2011		December 31, 2010
Prepaid taxes	$	14,128	$	7,411
Forward contract receivable	18,863		9,365
Other	17,858		10,135
	$	50,849	$	26,911

Schedule of Other Non-Current Assets



Other assets consist of the following:
	December 31, 2011		December 31, 2010
Forward contract receivable	$	6,465	$	590
Leasehold deposits	2,918		2,403
Other	3,135		1,579
	$	12,518	$	4,572

Property, Plant and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2011

Property, Plant and Equipment, Net [Abstract]

Schedule of Property, Plant and Equipment

A summary of property, plant and equipment is as follows:



Asset	December 31, 2011			December 31, 2010
Land	$	692		$	692
Buildings and improvements	141,157			133,430
Machinery and laboratory equipment	46,021			41,986
Computer hardware and software	27,788			20,012
Furniture and office equipment	7,163			5,340
Construction-in-progress	3,638			3,831
	226,459			205,291
Less: Accumulated depreciation and amortization	(60,607		)	(43,051		)
	$	165,852		$	162,240

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2011

Intangible Assets, Net [Abstract]

Schedule of Intangible Assets and Goodwill

Intangible assets and goodwill, net of accumulated amortization, are as follows:



		December 31, 2011							December 31, 2010
	Estimated Life (months)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licenses	28-96	$	23,648	$	(9,639	)	$	14,009	$	25,531	$	(8,251	)	$	17,280
Patents	90	10,517		(5,090		)	5,427		10,517		(3,651		)	6,866
Purchased technology	144	5,000		(382		)	4,618		—		—			—
Acquired IPR&D	Indefinite	67,550		—			67,550		—		—			—
Total		$	106,715	$	(15,111	)	$	91,604	$	36,048	$	(11,902	)	$	24,146
Goodwill	Indefinite	$	82,540	$	(2,901	)	$	79,639	$	22,855	$	(2,901	)	$	19,954

Schedule of Estimated Amortization of Intangible Assets

Assuming no changes in the gross cost basis of intangible assets, the estimated amortization of intangible assets for the next five fiscal years is as follows:



Year
2012	$	5,615
2013	7,212
2014	7,853
2015	424
2016	417

Schedule of Goodwill

The following table summarizes the changes in the carrying amount of goodwill:



Balance at December 31, 2010	$	19,954
Goodwill resulting from the Taligen acquisition	59,672
Goodwill resulting from the Orphatec acquisition	13
Balance at December 31, 2011	$	79,639

Tabular disclosure of goodwill by reportable segment and in total. Disclosure details may include, but are not limited to, the carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written-off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill.

Derivative Instruments and Hedging Activities [Abstract]

Derivative Instruments and Hedging Activities (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts



	December 31,
	2011			2010
Gain (loss) recognized in AOCI, net of tax	$	13,822		$	(2,760	)
Gain (loss) reclassified from AOCI to net product sales (Effective portion)	$	(6,558	)	$	8,778
Gain (loss) reclassified from AOCI to other income and expense (Ineffective portion)	$	(766	)	$	668

Schedule of Fair Value of Outstanding Derivatives



	December 31, 2011
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	$	14,118	Other current liabilities	$	5,889
Foreign exchange forward contracts	Other non-current assets	6,465		Other non-current liabilities	2,552
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	4,745		Other current liabilities	2,033
Total fair value of derivative instruments		$	25,328		$	10,474



	December 31, 2010
	Asset Derivatives			Liability Derivatives
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	$	8,015	Other current liabilities	$	7,124
Foreign exchange forward contracts	Other non-current assets	590		Other non-current liabilities	3,380
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Other current assets	1,350		Other current liabilities	4,724
Total fair value of derivative instruments		$	9,955		$	15,228

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2011

Accrued Liabilities [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following:



	December 31, 2011		December 31, 2010
Royalties	$	82,010	$	50,133
Payroll and employee benefits	39,453		24,034
Taxes payable	18,306		9,580
Rebates payable	21,746		4,660
Other	24,549		18,623
	$	186,064	$	107,030

Capital Leases (Tables)

12 Months Ended

Dec. 31, 2011

Leases, Capital [Abstract]

Schedule of Minimum Future Lease Payments Under Capital Lease

Minimum future lease payments under capital lease as of December 31, 2011 are:



Year
2012	$	779
2013	191
2014	3
	973
Less: Amount representing interest	64
Present value of minimum lease payments	$	909

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2011

Commitments and Contingencies Disclosure [Abstract]

Schedule of Aggregate Future Minimum Annual Rental Payments

Aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases (including facilities and equipment) as of December 31, 2011 are:



Year
2012	$	12,089
2013	10,146
2014	7,288
2015	4,652
2016	4,320
Thereafter	11,259

Schedule of Minimum Fixed Payments Due Under License and Research and Development Agreements

The minimum fixed payments (assuming non-termination of the above agreements) as of December 31, 2011, for each of the next five years are as follows:



Year	License Agreements		Clinical and Manufacturing Development Agreements
2012	$	253	$	40,200
2013	203		14,990
2014	203		15,000
2015	203		15,520
2016	203		16,070
	$	1,065	$	101,780

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2011

Income Tax Disclosure [Abstract]

Schedule of Income Tax Provision (Benefit) on Income Before Income Taxes

The income tax provision (benefit) is based on income before income taxes as follows:



	2011		2010		2009
U.S.	$	158,472	$	108,226	$	86,803
Non-U.S.	71,196		40,785		(3,489		)
	$	229,668	$	149,011	$	83,314

Schedule of Components of Income Tax Provision (Benefit)

The components of the income tax provision (benefit) are as follows:



	2011			2010			2009
Income Tax Provision (Benefit)
Domestic
Current	$	(904	)	$	5,013		$	(7,742	)
Deferred	45,463			40,569			(207,604		)
	44,559			45,582			(215,346		)
Foreign
Current	13,191			9,728			4,601
Deferred	(3,397		)	(3,329		)	(1,107		)
	9,794			6,399			3,494
Total
Current	12,287			14,741			(3,141		)
Deferred	42,066			37,240			(208,711		)
	$	54,353		$	51,981		$	(211,852	)

Reconciliation of the Statutory U.S. Federal Income Tax Rate to Effective Income Tax Rate

The reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate is as follows:



	December 31,
	2011		2010		2009
U.S. federal statutory tax rate	35.0	%	35.0	%	35.0	%
State and local income taxes	2.5	%	2.5	%	0.8	%
Foreign income tax rate differential	-9.4	%	-4.9	%	5.0	%
Income tax credits	-14.1	%	-1.0	%	-12.1	%
Foreign income subject to U.S. taxation	3.4	%	1.6	%	0.2	%
Stock option compensation	1.0	%	1.3	%	2.0	%
Non-deductible acquisition related costs	0.3	%	—	%	—	%
Other nondeductible and permanent differences	5.0	%	1.1	%	0.3	%
Provision (benefit) attributable to valuation allowances	—	%	-0.7	%	-285.5	%
Effective income tax rate	23.7	%	34.9	%	-254.3	%

Schedule of Components of Deferred Tax Assets and Liabilities

The components of the deferred tax assets and liabilities, which exclude "windfall" tax benefits, are as follows:



	December 31,			December 31,
	2011			2010
Deferred tax assets:
Net operating losses	$	54,421		$	126,111
Income tax credits	64,689			35,293
Stock compensation	22,459			16,814
Accruals and allowances	40,110			28,728
Intangible assets	—			8,013
	181,679			214,959
Valuation allowance	(3,074		)	(2,470		)
Total deferred tax assets	178,605			212,489
Deferred tax liabilities:
Depreciable assets	(40,760		)	(37,805		)
Intangible assets	(14,847		)	—
Unrealized gains	(860		)	(471		)
Total deferred tax liabilities	(56,467		)	(38,276		)
Net deferred tax asset	$	122,138		$	174,213

Reconciliation of Unrecognized Tax Benefits

The beginning and ending amounts of unrecognized tax benefits reconciles as follows:



	2011			2010			2009
Beginning of period balance	$	8,658		$	7,305		$	9,569
Increases for tax positions taken during a prior period	186			184			59
Decreases for tax positions taken during a prior period	(689		)	(22		)	(3,018		)
Increases for tax positions taken during the current period	1,692			1,191			695
Reduction as a result of a lapse of statute of limitations	—			—			—
Decreases for tax positions related to settlements	(74		)	—			—
	$	9,773		$	8,658		$	7,305

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Options and Restricted Stock (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Share-Based Compensation Capitalized to Inventory and Fixed Assets

The following table summarizes the components of share-based compensation expense in the consolidated statements of operations:



	December 31,
	2011		2010		2009
Cost of sales	$	2,375	$	1,266	$	—
Research and development	9,759		7,878		9,049
Selling, general and administrative	32,629		23,194		19,682
Total share-based compensation expense	$	44,763	$	32,338	$	28,731

The following table summarizes the share-based compensation capitalized to inventory and fixed assets:



	December 31,
	2011		2010		2009
Share-based compensation expense capitalized to inventory	$	2,954	$	2,785	$	1,403
Share-based compensation expense capitalized to fixed assets	$	—	$	—	$	970

Schedule of Status of Stock Option Plans

A summary of the status of our stock option plans at December 31, 2011, and changes during the year then ended is presented in the table and narrative below:



	Number of shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2010	12,228		$	15.27
Granted	2,556		45.38
Exercised	(2,744	)	13.05
Forfeited and cancelled	(274	)	36.20
Outstanding at December 31, 2011	11,766		$	21.83	6.76	$	584,395
Vested and unvested expected to vest at December 31, 2011	11,506		$	21.61	6.73	$	574,008
Exercisable at December 31, 2011	7,246		$	15.04	5.73	$	409,130

Schedule of Ranges of Weighted Average Assumptions

The fair value of options at the date of grant was estimated using the Black-Scholes model with the following ranges of weighted average assumptions:



	December 31,	December 31,	December 31,
	2011	2010	2009
Expected life in years	3.53 - 5.84	3.55 - 5.90	3.67 - 6.24
Interest rate	0.61% - 1.89%	0.84% - 2.16%	1.41% - 2.19%
Volatility	37.43% - 40.14%	40.70% - 42.48%	40.30% - 48.03%
Dividend yield	—	—	—

Schedule of Status of Non-Vested Restricted Stock

A summary of the status of our nonvested Restricted Stock and changes during the period then ended is as follows:



	December 31,
	2011
Nonvested Restricted Stock, beginning of period	2,122
Shares issued	807
Shares cancelled	(138	)
Shares vesting	(732	)
Nonvested Restricted Stock, end of period	2,059
Weighted average grant date fair value	$44.25

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

Schedule Of Assets And Liabilites Measured At Fair Value

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Abstract]



		Fair Value Measurement at December 31, 2011
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	428,431	$	—	$	428,431	$	—
Other current assets	Foreign exchange forward contracts	$	18,863	$	—	$	18,863	$	—
Other assets	Foreign exchange forward contracts	$	6,465	$	—	$	6,465	$	—
Other current liabilities	Foreign exchange forward contracts	$	7,922	$	—	$	7,922	$	—
Other liabilities	Foreign exchange forward contracts	$	2,552	$	—	$	2,552	$	—
Contingent consideration	Acquisition-related contingent consideration	$	18,120	$	—	$	—	$	18,120



		Fair Value Measurement at December 31, 2010
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Institutional money market funds	$	186,565	$	—	$	186,565	$	—
Marketable securities	Commercial paper	$	65,261	$	—	$	65,261	$	—
Marketable securities	U.S. Corporate bonds	$	19,184	$	—	$	19,184	$	—
Marketable securities	Federal agency obligations	$	10,015	$	—	$	10,015	$	—
Other current assets	Foreign exchange forward contracts	$	9,365	$	—	$	9,365	$	—
Other assets	Foreign exchange forward contracts	$	590	$	—	$	590	$	—
Other current liabilities	Foreign exchange forward contracts	$	11,848	$	—	$	11,848	$	—
Other liabilities	Foreign exchange forward contracts	$	3,380	$	—	$	3,380	$	—

Schedule Of Acquisition-Related Contingent Consideration

The following table represents a roll-forward of the fair value of Level 3 instruments, comprised solely of acquisition-related contingent consideration:



	December 31, 2011
Balance at beginning of period	$	—
Amounts acquired or issued	(16,720		)
Change in fair value	(1,400		)
Balance at end of period	$	(18,120	)

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Change in Benefit Obligation

The following table sets forth the funded status and the amounts recognized for defined benefit plans:



	December 31,
	2011			2010
Change in benefit obligation:
Projected benefit obligation, beginning of year	$	13,358		$	5,655
Prior service cost	—			76
Service cost	4,540			2,240
Interest cost	449			266
Change in assumptions	555			1,055
Recognized actuarial net loss	708			1,017
Foreign currency exchange rate changes	(214		)	929
Transfers into plan	(387		)	2,120
Projected benefit obligation, end of year	$	19,009		$	13,358
Accumulated benefit obligation, end of year	$	15,170		$	11,110

Schedule of Change in Plan Assets



	December 31,
	2011			2010
Change in plan assets:
Fair value of plan assets, beginning of year	$	9,542		$	4,737
Return on plan assets	197			108
Employer contributions	1,706			1,646
Plan participants' contributions	1,056			666
Foreign currency exchange rate changes	744			945
Transfers into plan	(387		)	1,440
Fair value of plan assets, end of year	$	12,858		$	9,542
Funded status at end of year	$	(6,151	)	$	(3,816	)

Schedule of Fair Value of Plan Assets and Target Asset Allocation

The following table provides information about the fair value of the plan assets per asset category:



	December 31, 2011				December 31, 2010
	Fair Value (Level 2)		as % of total plan assets		Fair Value (Level 2)		as % of total plan assets
Cash and cash equivalents	$	1,169	9	%	$	921	10	%
Equity security funds	3,661		28	%	2,473		26	%
Debt security funds	6,502		51	%	4,934		52	%
Real estate funds	1,526		12	%	1,214		12	%
	$	12,858	100	%	$	9,542	100	%

The targeted allocation for these funds (if any) is as follows:



	Target Allocation Ranges in %
Cash and notes receivable issued by banks or insurance companies	0-10%
Equity securities	8-20%
Debt securities	38-76%
Real estate	10-20%

Schedule of Weighted Average Assumptions Used to Calculate Net Periodic Benefit Cost and the Actuarial Present Value of Projected Benefit Obligations

The following table provides the weighted average assumptions used to calculate net periodic benefit cost and the actuarial present value of projected benefit obligations:



	December 31,
	2011		2010
Weighted average assumptions:
Discount rate	2.4	%	2.7	%
Long term rate of return on assets	4.0	%	4.0	%
Rate of compensation increase	1.0	%	1.5	%

Schedule of Components of Net Periodic Benefit Costs

The components of net periodic benefit cost are as follows:



	December 31,
	2011			2010
Service cost	$	4,540		$	2,240
Interest cost	449			266
Expected return on plan assets	(473		)	(265		)
Employee contributions	(1,056		)	(666		)
Amortization of prior service costs	9			8
Amortization and deferral of actuarial gain (loss)	305			35
Total net periodic benefit cost	$	3,774		$	1,618

Schedule of Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income

Other changes in plan assets and benefit obligations recognized in other comprehensive income (OCI) for the year ended December 31, 2011 are as follows:



Amount included in OCI-beginning of year	$	(3,018	)
Prior service cost	—
Net gain (loss) arising during the period	(639		)
Change in assumptions	(561		)
Amortization of net gain (loss)	242
Plan assets losses	(279		)
Taxes	72
Amount included in OCI-end of year	$	(4,183	)

Schedule of Estimated Future Benefit Payments

The expected future cash flows to be paid in respect of the pension plans as of December 31 were as follows:



Estimated future benefit payments
2012	$	937
2013	994
2014	977
2015	1,010
2016	916
2017 to 2021	5,137

Segment Information (Tables)

12 Months Ended

Dec. 31, 2011

Segment Reporting [Abstract]

Schedule of Revenues and Tangible Long-Lived Assets by Significant Geographic Region

Revenues and tangible long-lived assets by significant geographic region are as follows:



	December 31,
Revenues:	2011		2010		2009
United States	$	263,387	$	205,792	$	159,829
Europe	340,812		275,608		215,763
Asia Pacific (primarily Japan)	115,377		22,188		—
Other	63,855		37,369		11,208
	$	783,431	$	540,957	$	386,800

	December 31,
Long-lived assets (1):	2011		2010
United States	$	157,473	$	154,227
Europe	6,288		6,557
Other	2,091		1,456
	$	165,852	$	162,240


(1)	Long-lived assets consist of property, plant and equipment.

Quarterly Financial Information (unaudited) (Tables)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Information Disclosure [Abstract]

Schedule of Condensed Quarterly Financial Information

The following condensed quarterly financial information is for the years ended December 31, 2011 and 2010:



	Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2011:
Revenues	$	166,126	$	185,699	$	204,047	$	227,559
Cost of sales	19,228		21,745		23,369		28,798
Operating expenses (1)	106,665		114,930		114,479		123,391
Operating income	40,233		49,024		66,199		75,370
Net income	$	26,830	$	34,745	$	65,570	$	48,170
Earnings per common share (2)
Basic	$	0.15	$	0.19	$	0.36	$	0.26
Diluted	$	0.14	$	0.18	$	0.34	$	0.25

	March 31,		June 30,		September 30,		December 31,
2010:
Revenues	$	117,578	$	125,834	$	141,569	$	155,976
Cost of sales	13,999		13,721		16,495		20,222
Operating expenses	73,009		79,788		82,361		90,724
Operating income	30,570		32,325		42,713		45,030
Net income	$	20,934	$	21,773	$	27,873	$	26,450
Earnings per common share (2)
Basic	$	0.12	$	0.12	$	0.16	$	0.15
Diluted	$	0.11	$	0.12	$	0.15	$	0.14

Business Overview and Summary of Significant Accounting Policies (Narrative) (Details) - Years	12 Months Ended
	Dec. 31, 2011	May 20, 2011
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Percent of common stock dividend		100.00%
Inventory estimated life (in months)	48 months
Machinery and laboratory equipment
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated useful llfe, minimum	3
Property, Plant and Equipment, Estimated useful life, maximum	20
Building and improvements
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated useful llfe, minimum	5
Property, Plant and Equipment, Estimated useful life, maximum	30
Computer hardware and software
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated useful llfe, minimum	2
Property, Plant and Equipment, Estimated useful life, maximum	5
Furniture and office equipment
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated useful llfe, minimum	3
Property, Plant and Equipment, Estimated useful life, maximum	7
Minimum [Member]
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Average days' sales outstanding	30 days
Standard credit term, days	80 days
Maximum [Member]
Business Overview And Summary Of Significant Accounting Policies [Line Items]
Average days' sales outstanding	120 days
Standard credit term, days	100 days

Business Overview and Summary of Significant Accounting Policies (Accounts Receivable) (Details)	12 Months Ended
	Dec. 31, 2011 USD ($) Customers	Dec. 31, 2010 USD ($) Customers
Concentration Risk [Line Items]
Accounts receivable, current	$ 244,288,000	$ 168,732,000
Two Individual Customers [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers \| Customers	2
One Individual Customer [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers \| Customers		1
Major customer, percentage		18.00%
One Individual Customer [Member] \| Net Product Sales [Member]
Concentration Risk [Line Items]
Major customer, percentage		21.00%
Two Individual Customer, First Customer [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Major customer, percentage	18.00%
Two Individual Customer, First Customer [Member] \| Net Product Sales [Member]
Concentration Risk [Line Items]
Major customer, percentage	19.00%
Two Individual Customer, Second Customer [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Major customer, percentage	13.00%
Two Individual Customer, Second Customer [Member] \| Net Product Sales [Member]
Concentration Risk [Line Items]
Major customer, percentage	12.00%
Greece, Italy, Spain, Ireland and Portugal [Member]
Concentration Risk [Line Items]
Accounts receivable, current	$ 83,400
Allowance for doubtful accounts, current	3,500
Bad debt expense	4,100
Concentration Risk, Credit Risk [Member]
Concentration Risk [Line Items]
Accounts receivable, current	$ 24,000

Business Overview and Summary of Significant Accounting Policies (Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Business Overview and Summary of Significant Accounting Policies [Abstract]
Inventory, Raw Materials	$ 9,677	$ 4,835
Inventory, Work in Process	37,000	37,312
Inventory, Finished Goods	34,709	20,018
Inventory, Net	$ 81,386	$ 62,165

Business Overview and Summary of Significant Accounting Policies (Earnings Per Common Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2010

Sep. 30, 2010

Jun. 30, 2010

Mar. 31, 2010

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Business Overview and Summary of Significant Accounting Policies [Abstract]

Net income used for basic calculation

$ 48,170

$ 65,570

$ 34,745

$ 26,830

$ 26,450

$ 27,873

$ 21,773

$ 20,934

$ 175,315

$ 97,030

$ 295,166

Interest expense and debt financing cost amortization, net of tax, related to our 1.375% convertible senior notes

298

Net income used for diluted calculation

$ 175,341

$ 97,102

$ 295,464

Shares used in computing earnings per common share—basic

^[1]

183,220

178,542

170,652

Weighted-average effect of dilutive securities:

Shares issuable upon the assumed conversion of our 1.375% convertible senior notes

198

766

4,918

Stock awards

8,388

6,766

5,594

Dilutive potential common shares

8,586

7,532

10,512

Shares used in computing earnings per common share—diluted

^[1]

191,806

186,074

181,164

Earnings per common share

$ 0.26

^[2]

$ 0.36

^[2]

$ 0.19

^[2]

$ 0.15

^[2]

$ 0.15

^[2]

$ 0.16

^[2]

$ 0.12

^[2]

$ 0.12

^[2]

$ 0.96

^[1]

$ 0.54

^[1]

$ 1.73

^[1]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

$ 0.25

^[2]

$ 0.34

^[2]

$ 0.18

^[2]

$ 0.14

^[2]

$ 0.14

^[2]

$ 0.15

^[2]

$ 0.12

^[2]

$ 0.11

^[2]

$ 0.91

^[1]

$ 0.52

^[1]

$ 1.63

^[1]

Potentially dilutive securities:

1,920

2,474

4,494

Stock Options [Member]

Potentially dilutive securities:

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

1,905

2,468

4,480

Restricted Stock [Member]

Potentially dilutive securities:

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

[1]	Reflects the May 20, 2011, two-for-one stock split (refer to Note 1 for further discussion)
[2]	On May 20, 2011, we effected a two-for-one stock split, paid in the form of a 100% stock dividend. Stockholders of record at the close of trading on May 2, 2011 were issued one additional share of common stock for each share owned by such shareholder. All per share data presented in the accompanying table has been retroactively restated to reflect the stock split.

Business Overview and Summary of Significant Accounting Policies (Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated comprehensive income (loss), Beginning balance	$ (7,140)	$ (1,942)
Accumulated comprehensive income loss, Period change	11,319	(5,198)
Accumulated comprehensive income (loss), Ending balance	4,179	(7,140)
Pension Liability [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated comprehensive income (loss), Beginning balance	(3,018)	(1,120)
Accumulated comprehensive income loss, Period change	(1,165)	(1,898)
Accumulated comprehensive income (loss), Ending balance	(4,183)	(3,018)
Net Unrealized Gain(Loss) from Marketable Securities [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated comprehensive income (loss), Beginning balance	10	22
Accumulated comprehensive income loss, Period change	(10)	(12)
Accumulated comprehensive income (loss), Ending balance	0	10
Net Unrealized Gain(Loss) From Hedging Activities [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated comprehensive income (loss), Beginning balance	(2,501)	259
Accumulated comprehensive income loss, Period change	13,822	(2,760)
Accumulated comprehensive income (loss), Ending balance	11,321	(2,501)
Foreign Currency Translation Adjustment [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated comprehensive income (loss), Beginning balance	(1,631)	(1,103)
Accumulated comprehensive income loss, Period change	(1,328)	(528)
Accumulated comprehensive income (loss), Ending balance	$ (2,959)	$ (1,631)

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

This element represents Other Comprehensive Income or Loss, Net of Tax, for the period. Includes deferred gains or losses on qualifying hedges, unrealized holding gains or losses on available-for-sale securities, minimum pension liability, and cumulative translation adjustment. While for technical reasons this element has no balance attribute, the default assumption is a credit balance consistent with its label.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 22, 23, 24, 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e599-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Acquisitions (Narrative) (Details) $ in Thousands	3 Months Ended	12 Months Ended
Acquisitions (Narrative) (Details) $ in Thousands	Mar. 31, 2011 USD ($)	Dec. 31, 2011 USD ($) Months	Dec. 31, 2010 USD ($) Months	Dec. 31, 2009 USD ($)
Business Acquisition [Line Items]
Acquisition-related costs	$ 9,928	$ 13,486	$ 722	$ 0
Contingent consideration		18,120	0
Change in fair value of contingent consideration		(1,400)	0	$ 0
Intangible assets not amortizable		8,050
Deferred tax liabilities		56,467	38,276
Deferred tax liabilities, intangible assets		14,847	0
Deferred tax assets, tax credit carryforwards		64,689	$ 35,293
Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Business acquisition, cash paid		111,773
Acquisition-related costs		$ 10,375
Industrial index rate for discounting contingent consideration cash flows		4.90%
Contingent consideration		$ 12,684
Change in fair value of contingent consideration		$ 908
Finite-lived intangible assets, useful life		12
Rate of return on historical costs		25.00%
Deferred tax liabilities		$ 9,707
Deferred tax liabilities, intangible assets		21,545
Deferred tax assets, tax credit carryforwards		11,838
Estimated fair value of contingent consideration		11,634
Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Business acquisition, cash paid		3,050
Acquisition-related costs		1,072
Contingent consideration		5,436
Estimated fair value of contingent consideration		$ 5,086
Weighted cash flow discount rate for development milestone		4.90%
Weighted cash flow discount rate for commercial milestone		21.00%
Present value discount rate		23.00%
Minimum [Member] \| Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Business acquisition, additional contingent payments		$ 0
Minimum [Member] \| Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Business acquisition, additional contingent payments		0
Maximum [Member] \| Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Business acquisition, additional contingent payments		367,000
Maximum [Member] \| Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Business acquisition, additional contingent payments		$ 42,000
Purchased Technology [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets, useful life \| Months		144	144
In Process Research And Development Member \| Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Intangible assets not amortizable		$ 59,500
In Process Research And Development Member \| Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Intangible assets not amortizable		$ 8,050

Acquisitions (Reconciliation of Upfront Payments To Total Purchase Price) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($)
Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Upfront payment in accordance with agreement	$ 111,773
Separately-identifiable employee costs	(6,259)
Total consideration transferred	105,514
Estimated fair value of contingent consideration	11,634
Total purchase price	117,148
Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Upfront payment in accordance with agreement	3,050
Estimated fair value of contingent consideration	5,086
Total purchase price	$ 8,136

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6910544&loc=d3e4237-128469

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3629-128468

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910684&loc=d3e4570-128470

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(3),(c)(1)
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=6910544&loc=d3e4243-128469

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3642-128468

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 40
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910732&loc=d3e4805-128471

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer.

Acquisitions (Purchase Price Allocation To Assets Acquired And Liabilities Assumed) (Details) $ in Thousands	Dec. 31, 2011 USD ($)
Business Acquisition [Line Items]
In-process research and development	$ 8,050
Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Cash and cash equivalents	2,678
Other assets	555
Assets acquired	67,733
Deferred tax liability (net)	(9,173)
Other liabilities assumed	(1,084)
Liabilities assumed	(10,257)
Goodwill	59,672
Net assets acquired	117,148
Taligen Therapeutics Inc Member \| Purchased Technology [Member]
Business Acquisition [Line Items]
Purchased technology	5,000
Taligen Therapeutics Inc Member \| In Process Research And Development Member
Business Acquisition [Line Items]
In-process research and development	59,500
Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Other assets	73
Assets acquired	8,123
Goodwill	13
Net assets acquired	8,136
Orphatec Pharmaceuticals Gmbh Member \| In Process Research And Development Member
Business Acquisition [Line Items]
In-process research and development	$ 8,050

Acquisitions (Pro Forma Financial Information Of Combined Results Of Operations) (Details) - Taligen Therapeutics Inc Member - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Business Acquisition [Line Items]
Revenues	$ 783,431	$ 541,413
Net income	$ 174,209	$ 84,662
Earnings per common share, Basic	$ 0.95	$ 0.47
Earnings per common share, Diluted	$ 0.91	$ 0.45

The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.

Acquisitions (Acquisition Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs	$ 9,928	$ 13,486	$ 722	$ 0
Taligen Therapeutics Inc Member
Business Acquisition [Line Items]
Separately-identifiable employee costs		6,597
Professional fees		2,728
Changes in fair value of contingent consideration		1,050
Business Combination, Acquisition Related Costs		10,375
Orphatec Pharmaceuticals Gmbh Member
Business Acquisition [Line Items]
Professional fees		722
Changes in fair value of contingent consideration		350
Business Combination, Acquisition Related Costs		$ 1,072

Marketable Securities (Details) - USD ($) $ in Thousands	12 Months Ended
Marketable Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Schedule of Investment Income, Reported Amounts, by Category [Line Items]
Marketable securities, amortized cost basis		$ 94,433
Marketable securities, gross unrealized holding gains		62
Marketable securities, gross unrealized holding losses		(35)
Marketable securities, other than temporary impairments		0
Marketable securities, aggregate fair value	$ 0	94,460
Marketable securities, realized gains and losses	$ 0	0	$ 0
Commercial Paper [Member]
Schedule of Investment Income, Reported Amounts, by Category [Line Items]
Marketable securities, amortized cost basis		65,244
Marketable securities, gross unrealized holding gains		44
Marketable securities, gross unrealized holding losses		(27)
Marketable securities, other than temporary impairments		0
Marketable securities, aggregate fair value		65,261
Corporate Bonds [Member]
Schedule of Investment Income, Reported Amounts, by Category [Line Items]
Marketable securities, amortized cost basis		19,186
Marketable securities, gross unrealized holding gains		6
Marketable securities, gross unrealized holding losses		(8)
Marketable securities, other than temporary impairments		0
Marketable securities, aggregate fair value		19,184
Federal Agency Obligations [Member]
Schedule of Investment Income, Reported Amounts, by Category [Line Items]
Marketable securities, amortized cost basis		10,003
Marketable securities, gross unrealized holding gains		12
Marketable securities, gross unrealized holding losses		0
Marketable securities, other than temporary impairments		0
Marketable securities, aggregate fair value		$ 10,015

Prepaid Expenses and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Prepaid Expense and Other Assets [Line Items]
Prepaid taxes	$ 14,128	$ 7,411
Other	17,858	10,135
Other Assets, Current	50,849	26,911
Forward contract receivable	25,328	9,955
Leasehold deposits	2,918	2,403
Other	3,135	1,579
Other assets	12,518	4,572
Other Current Assets [Member]
Prepaid Expense and Other Assets [Line Items]
Forward contract receivable	18,863	9,365
Other Non Current Assets [Member]
Prepaid Expense and Other Assets [Line Items]
Forward contract receivable	$ 6,465	$ 590

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Property, Plant and Equipment [Line Items]
Land	$ 692	$ 692
Buildings and improvements	141,157	133,430
Machinery and laboratory equipment	46,021	41,986
Computer hardware and software	27,788	20,012
Furniture and office equipment	7,163	5,340
Construction-in-progress	3,638	3,831
Property, Plant and Equipment, Gross	226,459	205,291
Less: Accumulated depreciation and amortization	(60,607)	(43,051)
Property, Plant and Equipment, Net	165,852	162,240
Depreciation and amortization of property, plant and equipment	17,616	15,792	$ 12,473
Computer software costs	10,303	7,368
Computer software, depreciation and amortization expense	3,642	2,883	2,091
Property, pland and equipment reclassification adjustment			4,514
Capitalized interest			3,427
Property, Plant, and Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation and amortization of property, plant and equipment	$ 12,236	$ 11,003	$ 7,566

Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($) Months	Dec. 31, 2010 USD ($) Months
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Cost	$ 67,550
Intangible Assets, Cost	106,715	$ 36,048
Intangible Assets, Accumulated Amortization	15,111	11,902
Intangible assets, net	91,604	24,146
Goodwill, Cost	82,540	22,855
Goodwill, Accumulated Amortization	(2,901)	(2,901)
Goodwill, Net	79,639	19,954
Licensing Agreements [Member]
Intangible Assets [Line Items]
Finite-lived Intangible Assets, Cost	23,648	25,531
Finite-lived Intangible Assets, Accumulated Amortization	(9,639)	(8,251)
Finite-lived Intangible Assets, Net	$ 14,009	$ 17,280
Intangible Assets, Estimated Life (months), Minimum \| Months	28	28
Intangible Assets, Estimated Life (months), Maximum \| Months	96	96
Patents [Member]
Intangible Assets [Line Items]
Finite-lived Intangible Assets, Cost	$ 10,517	$ 10,517
Finite-lived Intangible Assets, Accumulated Amortization	(5,090)	(3,651)
Finite-lived Intangible Assets, Net	$ 5,427	$ 6,866
Intangible Assets, Estimated Life (months) \| Months	90	90
Purchased Technology [Member]
Intangible Assets [Line Items]
Finite-lived Intangible Assets, Cost	$ 5,000	$ 0
Finite-lived Intangible Assets, Accumulated Amortization	(382)	0
Finite-lived Intangible Assets, Net	$ 4,618	$ 0
Intangible Assets, Estimated Life (months) \| Months	144	144
Acquired IPR&D [Member]
Intangible Assets [Line Items]
Indefinite-lived Intangible Assets, Cost	$ 67,550	$ 0
Indefinite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-Lived Intangible Assets, Net	$ 67,550	$ 0

Intangible Assets and Goodwill (Amortization of Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Intangible Assets, Net [Abstract]
Amortization of intangible assets	$ 5,087	$ 4,552	$ 4,663
2012	5,615
2013	7,212
2014	7,853
2015	424
2016	$ 417

Intangible Assets and Goodwill (Schedule of Changes in the Carrying Amount of Goodwill) (Details) $ in Thousands	Dec. 31, 2011 USD ($)
Goodwill [Line Items]
Indefinite-lived Intangible Assets	$ 67,550
Taligen Therapeutics Inc Member
Goodwill [Line Items]
Indefinite-lived Intangible Assets	59,500
Goodwill acquired during period	59,672
Orphatec Pharmaceuticals Gmbh Member
Goodwill [Line Items]
Indefinite-lived Intangible Assets	8,050
Goodwill acquired during period	$ 13

Derivative Instruments and Hedging Activities (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($) Days Months	Dec. 31, 2010 USD ($)
Derivative Instruments and Hedging Activities [Abstract]
Foreign exchange forward contracts durations (months) \| Months	36
Cash flow hedges notional amounts	$ 520,743
Reclassified loss on other comprehenisve income	$ 8,046
Foreign exchange forward contracts durations (days) \| Days	30
Notional amount of foreign exchange contracts that do not qualify for hedge accounting	$ 171,834
Gain on other income and expense	$ 790	$ 9,443

Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Derivative Instruments and Hedging Activities [Abstract]
Gain (loss) recognized in AOCI, net of tax	$ 13,822	$ (2,760)
Gain (loss) reclassified from AOCI to net product sales (Effective portion)	(6,558)	8,778
Gain (loss) reclassified from AOCI to other income and expense (Ineffective portion)	$ (766)	$ 668

Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 25,328	$ 9,955
Liability Derivatives, Fair Value	10,474	15,228
Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	18,863	9,365
Other Non Current Assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6,465	590
Foreign Exchange Forward [Member] \| Other Current Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	14,118	8,015
Foreign Exchange Forward [Member] \| Other Current Assets [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	4,745	1,350
Foreign Exchange Forward [Member] \| Other Current Liabilities [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	5,889	7,124
Foreign Exchange Forward [Member] \| Other Current Liabilities [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	2,033	4,724
Foreign Exchange Forward [Member] \| Other Non Current Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6,465	590
Foreign Exchange Forward [Member] \| Other Non Current Liabilities [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 2,552	$ 3,380

Accrued Expenses (Schedule of Accrued Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Accrued Liabilities [Abstract]
Royalties	$ 82,010	$ 50,133
Payroll and employee benefits	39,453	24,034
Taxes payable	18,306	9,580
Rebates payable	21,746	4,660
Other	24,549	18,623
Accrued expenses	$ 186,064	$ 107,030

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Debt (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended				12 Months Ended
Debt (Details) $ / shares in Units, $ in Thousands	Feb. 29, 2012 shares	Jan. 31, 2005 USD ($) shares $ / shares	Jun. 30, 2011 USD ($) shares	Jun. 30, 2010 USD ($) shares	Mar. 31, 2010 USD ($) shares	Jun. 30, 2009 USD ($) shares	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Feb. 07, 2012 USD ($)	Mar. 31, 2011 USD ($)
Debt Instrument [Line Items]
Non-cash expense for fair value of additional shares over the stated conversion rate							$ 0	$ 0	$ 3,395
Amount of senior notes outstanding							718	0
Convertible Senior Notes [Member] \| One Point Three Seven Five Percent Convertible Senior Notes Due February 2012 [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 150,000
Debt instrument, stated interest rate		1.375%
Debt instrument, conversion rate \| shares		127.1656
Debt instrument, conversion price \| $ / shares		$ 7.87
Debt instrument, aggregate principal amount			$ 3,000	$ 5,200	$ 1,000	$ 87,304
Additional shares of common stock issued for a conversion of principal amount \| shares	91,000		190,747,000	330,629,000	63,582,000	5,644,000
Non-cash expense for fair value of additional shares over the stated conversion rate						$ 3,395
Deferred financing costs reclassified to equity as a result of conversion						1,105
Amount of senior notes outstanding						$ 272	718
Fair value of senior notes outstanding							6,612
Amortization expense associated with deferred financing costs							283	$ 239	$ 260
Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity											$ 100,000
Sublimit for letter of credit for working capital requirements and other general corporate purposes											20,000
Possible future increase in credit facility											$ 150,000
Revolving credit facility, amount outstanding							0
Letters of credit, amount outstanding							3,754
Line of credit facility, borrowing availability							$ 96,000
LIBOR Plus [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, description of variable rate basis							LIBOR
LIBOR Plus [Member] \| Minimum [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on varaible rate							1.75%
LIBOR Plus [Member] \| Maximum [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on varaible rate							2.25%
Prime Rate [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, description of variable rate basis							Prime Rate
Federal Funds Rate [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, description of variable rate basis							Federal Funds Rate
Debt instrument, basis spread on varaible rate							0.50%
Eurodollar Rate [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, description of variable rate basis							Eurodollar Rate
Debt instrument, basis spread on varaible rate							1.00%
Eurodollar Rate [Member] \| Minimum [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on varaible rate							0.75%
Eurodollar Rate [Member] \| Maximum [Member] \| Line of Credit [Member] \| Amended Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, basis spread on varaible rate							1.25%
Issuance of Debt [Member] \| Enobia Pharma, Inc. [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity										$ 440,000
Term of credit facility	5 years

Capital Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Debt Instrument [Line Items]
Cost of equipment under capital lease	$ 2,692	$ 2,642
Accumulated amortization of equipment under capital lease	1,524	$ 958
2012	779
2013	191
2014	3
Future minimum payments due	973
Less: Amount representing interest	64
Present value of minimum lease payments	$ 909
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Debt, weighted average interest rate	4.04%

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Commitments and Contingencies [Line Items]
Remaining total commitments with Lonza	$ 136,000
Accrued royalties	82,010	$ 50,133
Lease expense for facilities	10,424	$ 6,980	$ 6,817
Minimum [Member]
Commitments and Contingencies [Line Items]
Monthly fixed rent for operating lease	162
Maximum [Member]
Commitments and Contingencies [Line Items]
Monthly fixed rent for operating lease	$ 232

Commitments and Contingencies (Schedule of Aggregate Future Minimum Annual Rental Payments) (Details) $ in Thousands	Dec. 31, 2011 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2012	$ 12,089
2013	10,146
2014	7,288
2015	4,652
2016	4,320
Thereafter	$ 11,259

Commitments and Contingencies (Schedule of Minimum Fixed Payments Due Under License and Research and Development Agreements) (Details) $ in Thousands	Dec. 31, 2011 USD ($)
License Agreements [Member]
Commitments and Contingencies [Line Items]
2012	$ 253
2013	203
2014	203
2015	203
2016	203
Future fixed minimum payments due	1,065
Clinical and Manufacturing Development Agreements
Commitments and Contingencies [Line Items]
2012	40,200
2013	14,990
2014	15,000
2015	15,520
2016	16,070
Future fixed minimum payments due	$ 101,780

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Contingency [Line Items]
Cumulative changes in ownership interest percent threshold		50.00%
Income tax provision (benefit)		$ 54,353	$ 51,981	$ (211,852)
Interest accrued and penalties related to unrecognized tax benefits		$ 442
Statute of limitations, minimum (years)		3 years
Statute of limitations, maximum (years)		5 years
Tax holiday expected renewal period (years)		5 years
Federal [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards		$ 464,918
Income tax credit carryforwards		72,278
State [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards		109,095
Income tax credit carryforwards		1,361
Excess Tax Benefits from Exercise of Non-qualified Stock Options [Member] \| Federal [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards		315,689
Excess Tax Benefits from Exercise of Non-qualified Stock Options [Member] \| State [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards		49,911
Portion Attributable to Excess Tax Benefits from the Exercise of Non-Qualified Stock Options [Member] \| Federal [Member]
Income Tax Contingency [Line Items]
Income tax credit carryforwards		8,473
Federal Foreign Tax And Orphan Drug Credit [Member]
Income Tax Contingency [Line Items]
Income tax provision (benefit)	$ 15,400
Taligen Therapeutics Inc Member \| Federal [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards		36,500
Taligen Therapeutics Inc Member \| State [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards		$ 28,300

Income Taxes (Schedule of Income Tax Provision (Benefit) on Income Before Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Disclosure [Abstract]
U.S.	$ 158,472	$ 108,226	$ 86,803
Non-U.S.	71,196	40,785	(3,489)
Income before income taxes	$ 229,668	$ 149,011	$ 83,314

Income Taxes (Schedule of Components of Income Tax Provision (Benefit)) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Domestic
Current	$ (904)	$ 5,013	$ (7,742)
Deferred	45,463	40,569	(207,604)
Total Domestic	44,559	45,582	(215,346)
Foreign
Current	13,191	9,728	4,601
Deferred	(3,397)	(3,329)	(1,107)
Total Foreign	9,794	6,399	3,494
Total
Current	12,287	14,741	(3,141)
Deferred	42,066	37,240	(208,711)
Income Tax Expense (Benefit)	$ 54,353	$ 51,981	$ (211,852)

Income Taxes (Reconciliation of the Statutory U.S. Federal Income Tax Rate to Effective Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	35.00%	35.00%	35.00%
State and local income taxes	2.50%	2.50%	0.80%
Foreign income tax rate differential	(9.40%)	(4.90%)	5.00%
Income tax credits	(14.10%)	(1.00%)	(12.10%)
Foreign income subject to U.S. taxation	3.40%	1.60%	0.20%
Stock option compensation	1.00%	1.30%	2.00%
Non-deductible acquistion related costs	0.30%	0.00%	0.00%
Other nondeductible and permanent differences	5.00%	1.10%	0.30%
Provision (benefit) attributable to valuation allowances	0.00%	(0.70%)	(285.50%)
Effective income tax rate	23.70%	34.90%	(254.30%)

Income Taxes (Schedule of Components of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Deferred tax assets:
Net operating losses	$ 54,421	$ 126,111
Income tax credits	64,689	35,293
Stock compensation	22,459	16,814
Accruals and allowances	40,110	28,728
Intangible assets	0	8,013
Gross deferred tax assets	181,679	214,959
Valuation allowance	(3,074)	(2,470)
Total deferred tax assets	178,605	212,489
Deferred tax liabilities:
Depreciable assets	(40,760)	(37,805)
Intangible assets	(14,847)	0
Unrealized gains	(860)	(471)
Total deferred tax liabilities	(56,467)	(38,276)
Net deferred tax asset	$ 122,138	$ 174,213

Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of period balance	$ 8,658	$ 7,305	$ 9,569
Increases for tax positions taken during a prior period	186	184	59
Decreases for tax positions taken during a prior period	(689)	(22)	(3,018)
Increases for tax positions taken during the current period	1,692	1,191	695
Reduction as a result of a lapse of statute of limitations	0	0	0
Decreases for tax positions related to settlements	(74)	0	0
End of period balance	$ 9,773	$ 8,658	$ 7,305

Stock Options and Restricted Stock (Narrative) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($) Years $ / shares shares	Dec. 31, 2010 USD ($) $ / shares	Dec. 31, 2009 USD ($) $ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Maximum stock option shared authorized \| shares	29,874
Maximum contractual term under all plans (in years)	10
General vesting period (in years)	4 years
Weighted average fair value at the date of grant for options granted \| $ / shares	$ 15.46	$ 8.50	$ 7.48
Total compensation cost not yet recognized on non-vested awards	$ 78,817
Period for rececognition for compensation cost not yet recognized of non-vested awards \| Years	2.69
Total intrinsic value of stock options exercised	$ 114,712	$ 64,656	$ 33,335
Total fair value of shares vested	$ 23,485	$ 20,039	$ 20,734

Stock Options and Restricted Stock (Schedule of Components of Allocated Share-Based Compensation Expense and Capitalization of Share Based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 44,763	$ 32,338	$ 28,731
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	2,375	1,266	0
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	9,759	7,878	9,049
Selling General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	32,629	23,194	19,682
Inventory [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Capitalized share-based compensation costs	2,954	2,785	1,403
Fixed Assets [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Capitalized share-based compensation costs	$ 0	$ 0	$ 970

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

Stock Options and Restricted Stock (Schedule of Status of Stock Option Plans) (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($) Years $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of shares \| shares	12,228
Outstanding at beginning of period, Weighted Average Exercise Price \| $ / shares	$ 15.27
Granted, Number of shares \| shares	2,556
Granted, Weighted Average Exercise Price \| $ / shares	$ 45.38
Exercised, Number of shares \| shares	(2,744)
Exercised, Weighted Average Exercise Price \| $ / shares	$ 13.05
Forfeited and cancelled, Number of shares \| shares	(274)
Forfeited and cancelled, Weighted Average Exercise Price \| $ / shares	$ 36.20
Outstanding at end of period, Number of shares \| shares	11,766
Outstanding at end of period, Weighted Average Exercise Price \| $ / shares	$ 21.83
Outstanding at end of period, Weighted Average Remaining Contractual Term (in years) \| Years	6.76
Outstanding at end of period, Aggregate Intrinsic Value \| $	$ 584,395
Vested and unvested expected to vest at end of period, Number of shares \| shares	11,506
Vested and unvested expected to vest at end of period, Weighted Average Exercise Price \| $ / shares	$ 21.61
Vested and unvested expected to vest at end of period, Weighted Average Remaining Contractual Term (in years) \| Years	6.73
Vested and unvested expected to vest at end of period, Aggregate Intrinsic Value \| $	$ 574,008
Exercisable at end of period, Number of shares \| shares	7,246
Exercisable at end of period, Weighted Average Exercise Price \| $ / shares	$ 15.04
Exercisable at end of period, Weighted Average Remaining Contractual Term (in years) \| Years	5.73
Exercisable at end of period, Aggregate Intrinsic Value \| $	$ 409,130

Stock Options and Restricted Stock (Schedule of Ranges of Weighted Average Assumptions) (Details) - Years	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected life in years, minimum	3.53	3.55	3.67
Expected life in years, maximum	5.84	5.90	6.24
Interest rate, minimum	0.61%	0.84%	1.41%
Interest rate, maximum	1.89%	2.16%	2.19%
Volatility, minimum	37.43%	40.70%	40.30%
Volatility, maximum	40.14%	42.48%	48.03%
Dividend yield	0.00%	0.00%	0.00%

Stock Options and Restricted Stock (Schedule of Status of Non-Vested Restricted Stock) (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2011 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Nonvested restricted stock, beginning of period	2,122
Shares issued	807
Shares cancelled	(138)
Shares vesting	(732)
Nonvested restricted stock, end of period	2,059
Weighted average grant date fair value \| $ / shares	$ 44.25

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

Common and Preferred Stock Common and Preferred Stock (Details)	Dec. 31, 2011	Aug. 22, 2008 $ / shares	Feb. 28, 1997 $ / shares shares
Common and Preferred Stock [Abstract]
Number of preferred shares for each share of common stock \| shares			1
Percent of each right exercised to purchase a share of a new series of preferred stock		2.00%	1.00%
Preferred share, exercise price			$ 75.00
Acquisition of common stock threshold percentage that allows rights to be exercised			20.00%
Preferred stock, redemption price per share			$ 0.01
Preferred stock, minimum preferential dividend			10.00
Preferred stock, liquidation preference per share			$ 100
Aggregate liquidation payment factor			100
Purchase price of a share of preferred stock to be issued upon the exercise of each preferred stock purchase right		$ 300.00
Threshold percentage for sale of asssets, cash flow, or earning power	50.00%
Exercise price of right market value factor	2

Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 18,120	$ 0
Institutional Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	428,431	186,565
Institutional Money Market Funds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Institutional Money Market Funds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	428,431	186,565
Institutional Money Market Funds [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		65,261
Commercial Paper [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		0
Commercial Paper [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		65,261
Commercial Paper [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		0
U.S. Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		19,184
U.S. Corporate Bonds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		0
U.S. Corporate Bonds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		19,184
U.S. Corporate Bonds [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		0
Federal Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		10,015
Federal Agency Obligations [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		0
Federal Agency Obligations [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		10,015
Federal Agency Obligations [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		0
Acquisition Related Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	18,120
Acquisition Related Contingent Consideration [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Acquisition Related Contingent Consideration [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0
Other Current Assets [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	18,863	9,365
Other Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	18,863	9,365
Other Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Non Current Assets [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	6,465	590
Other Non Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Non Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	6,465	590
Other Non Current Assets [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, asset	0	0
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	7,922	11,848
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	7,922	11,848
Other Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Other Non Current Liabilities [Member] \| Foreign Exchange Forward [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	2,552	3,380
Other Non Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	0	0
Other Non Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	2,552	3,380
Other Non Current Liabilities [Member] \| Foreign Exchange Forward [Member] \| Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange forward contracts, liability	$ 0	$ 0

Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)	12 Months Ended
	Dec. 31, 2011 USD ($)
Acquisition-Related Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 0
Amounts acquired or issued	(16,720,000)
Change in fair value	(1,400,000)
Balance at end of period	$ (18,120,000)

Employee Benefit Plans (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Compensation and Retirement Disclosure [Abstract]
Amount of each dollar matching contributed up to first four percent of individual base salary and incentive cash bonus	$ 1.00
Percentage of contribution of individual's base salary and incentive cash bonus	4.00%
Amount of each dollar matching contributed of next two percent of individual base salary and incentive cash bonus	$ 0.50
Percentage of contribution of compensation	2.00%
Defined benefit plan, contributions by employer	$ 2,882	$ 1,893	$ 1,552
Additional minimum liability recorded in other non-current liabiliites	6,151
Additional minimum liability charged against other comprehensive income	4,183
Estimated future employer contributions in next fiscal year	$ 2,560

This represents the noncurrent liability for underfunded plans recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement defined benefit plans.

Employee Benefit Plans (Schedule of Change in Benefit Obligation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Change in benefit obligation:
Projected benefit obligation, beginning of year	$ 13,358	$ 5,655
Prior service cost	0	76
Service cost	4,540	2,240
Interest cost	449	266
Change in assumptions	555	1,055
Recognized actuarial net loss	708	1,017
Foreign currency exchange rate changes	(214)	929
Transfers into plan	(387)	2,120
Projected benefit obligation, end of year	19,009	13,358
Accumulated benefit obligation, end of year	$ 15,170	$ 11,110

Employee Benefit Plans (Schedule of Change in Plan Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Change in plan assets:
Fair value of plan assets, beginning of year	$ 9,542	$ 4,737
Return on plan assets	197	108
Employer contributions	1,706	1,646
Plan participants' contributions	1,056	666
Foreign currency exchange rate changes	744	945
Transfers into plan	(387)	1,440
Fair value of plan assets, end of year	12,858	9,542
Funded status at end of year	$ (6,151)	$ (3,816)

The difference between fair value of plan assets at the end of the period and the fair value at the beginning of the period, adjusted for contributions and payments of benefits during the period, and after adjusting for taxes and other expenses, as applicable.

The amount of payments made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. This item represents a periodic decrease to the plan obligations and a decrease to plan assets.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Postretirement Benefits
-URI http://asc.fasb.org/extlink&oid=6521376

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(5)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Benefits
-URI http://asc.fasb.org/extlink&oid=6506267
-Topic 715
-SubTopic 30

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(6)
-URI http://asc.fasb.org/extlink&oid=6962843&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Benefits
-URI http://asc.fasb.org/extlink&oid=6506309
-Topic 715
-SubTopic 60

Assets, usually stocks, bonds, and other investments, that have been segregated and restricted (usually in a trust) to provide benefits, at their fair value as of the measurement date. Plan assets include amounts contributed by the employer (and by employees for a contributory plan) and amounts earned from investing the contributions, less benefits paid. If a plan has liabilities other than for benefits, those non-benefit obligations may be considered as reductions of plan assets.

Employee Benefit Plans (Schedule of Fair Value of Plan Assets and Target Asset Allocation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, end of year	$ 12,858
Actual plan asset allocations	100.00%	100.00%
Cash and notes receivable issued by banks or insurance companies, minimum	0.00%
Cash and notes receivable issued by banks or insurance companies, maximum	10.00%
Equity securities, minimum	8.00%
Equity securities, maximum	20.00%
Debt securities, minimum	38.00%
Debt securities, maximum	76.00%
Real estate, minimum	10.00%
Real estate, maximum	20.00%
Fair Value (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, end of year	$ 12,858
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Actual plan asset allocations	9.00%	10.00%
Cash and Cash Equivalents [Member] \| Fair Value (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, end of year	$ 1,169
Equity Security Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Actual plan asset allocations	28.00%	26.00%
Equity Security Funds [Member] \| Fair Value (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, end of year	$ 3,661
Debt Security Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Actual plan asset allocations	51.00%	52.00%
Debt Security Funds [Member] \| Fair Value (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, end of year	$ 6,502
Real Estate Funds [Member]
Defined Benefit Plan Disclosure [Line Items]
Actual plan asset allocations	12.00%	12.00%
Real Estate Funds [Member] \| Fair Value (Level 2) [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets, end of year	$ 1,526

Employee Benefit Plans (Schedule of Weighted Average Assumptions Used to Calculate Net Periodic Benefit Cost and the Actuarial Present Value of Projected Benefit Obligations) (Details)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Compensation and Retirement Disclosure [Abstract]
Discount rate	2.40%	2.70%
Long term rate of return on assets	4.00%	4.00%
Rate of compensation increase	1.00%	1.50%

Employee Benefit Plans (Schedule of Components of Net Periodic Benefit Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Compensation and Retirement Disclosure [Abstract]
Service cost	$ 4,540	$ 2,240
Interest cost	449	266
Expected return on plan assets	(473)	(265)
Employee contributions	(1,056)	(666)
Amortization of prior service costs	9	8
Amortization and deferral of actuarial gain (loss)	305	35
Total net periodic benefit cost	$ 3,774	$ 1,618

An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets.

The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.

The actuarial present value of benefits attributed by the pension benefit formula to services rendered by employees during the period. The portion of the expected postretirement benefit obligation attributed to employee service during the period. The service cost component is a portion of the benefit obligation and is unaffected by the funded status of the plan.

Employee Benefit Plans (Schedule of Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($)
Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income [Roll Forward]
Amount included in OCI-beginning of year	$ (3,018)
Prior service cost	0
Net gain (loss) arising during the period	(639)
Change in assumptions	(561)
Amortization of net gain (loss)	242
Plan assets losses	(279)
Taxes	72
Amount included in OCI-end of year	$ (4,183)

The change in other comprehensive income due to the amortization of the net prior service costs (credit) into net periodic pension costs.

The pretax cost (credit) of benefit changes attributable to plan participants' prior service resulting from a plan amendment or plan initiation that occurred during the period. The cost has not yet been recognized in net periodic benefit cost. A plan amendment includes provisions that grant increased (decreased) benefits based on service rendered in prior periods.

Amounts recognized in other comprehensive income (but not yet recognized in net periodic benefit cost), including the net gain (loss) and net prior service cost (credit) arising during the period. Also includes reclassification adjustments out of other comprehensive income as a result of being recognized as components of net periodic benefit cost for the period. While for technical reasons this element has no balance attribute, the default assumption is a credit balance consistent with its label.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph C3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 22, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (h)-(j)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Revenues from External Customers and Long-Lived Assets [Line Items]

Employee Benefit Plans (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Dec. 31, 2011 USD ($)
Compensation and Retirement Disclosure [Abstract]
2012	$ 937
2013	994
2014	977
2015	1,010
2016	916
2017 to 2021	$ 5,137

Segment Information (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

$ 783,431

$ 540,957

$ 386,800

Revenues from External Customers and Long-Lived Assets [Line Items]

^[1]

165,852

162,240

United States [Member]

263,387

205,792

159,829

Revenues from External Customers and Long-Lived Assets [Line Items]

^[1]

157,473

154,227

Europe [Member]

340,812

275,608

215,763

Asia Pacific (primarily Japan) [Member]

^[1]

6,288

6,557

Revenues from External Customers and Long-Lived Assets [Line Items]

Revenues from External Customers and Long-Lived Assets [Line Items]

115,377

22,188

Other [Member]

63,855

37,369

$ 11,208

Quarterly Financial Information Disclosure [Abstract]

^[1]

$ 2,091

$ 1,456

[1]

rcialization of life-transforming therapeutic products and therefore, our chief operating decision-maker manages the operations of our Company as a single operating segment. Revenues and tangible long-lived assets by significant geographic region are as follows: December 31,Revenues:2011 2010 2009United States$263,387 $205,792 $159,829Europe340,812 275,608 215,763Asia Pacific (primarily Japan)115,377 22,188 —Other63,855 37,369 11,208 $783,431 $540,957 $386,800 December 31, Long-lived assets (1):2011 2010 United States$157,473 $154,227 Europe6,288 6,557 Other2,091 1,456 $165,852 $162,240 (1)Long-lived assets consist of property, plant and equipment.

Subsequent Events (Details) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended					12 Months Ended
	Feb. 29, 2012	Jun. 30, 2011	Mar. 31, 2011	Jun. 30, 2010	Mar. 31, 2010	Jun. 30, 2009	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Feb. 07, 2012	Jan. 31, 2005
Subsequent Event [Line Items]
Accrued professional fees			$ 9,928				$ 13,486	$ 722	$ 0
Senior Notes [Member] \| One Point Three Seven Five Percent Convertible Senior Notes Due February 2012 [Member]
Subsequent Event [Line Items]
Debt instrument, stated interest rate											1.375%
Additional shares of common stock issued for a conversion of principal amount	91	190,747		330,629	63,582	5,644
Issuance of Debt [Member] \| Enobia Pharma, Inc. [Member] \| Line of Credit [Member]
Subsequent Event [Line Items]
Term of credit facility	5 years
Line of credit facility, maximum borrowing capacity										$ 440,000
Issuance of Debt [Member] \| Enobia Pharma, Inc. [Member] \| Term Loan [Member]
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity										240,000
Issuance of Debt [Member] \| Enobia Pharma, Inc. [Member] \| Revolving Line of Credit [Member]
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity										200,000
Line of credit facility, installments	$ 12,000
Debt instrument, description of variable rate basis	LIBOR
Revolving credit facility, amount outstanding										$ 80,000
Issuance of Debt [Member] \| Minimum [Member] \| Enobia Pharma, Inc. [Member] \| Revolving Line of Credit [Member]
Subsequent Event [Line Items]
Debt instrument, basis spread on varaible rate										1.25%
Issuance of Debt [Member] \| Maximum [Member] \| Enobia Pharma, Inc. [Member] \| Revolving Line of Credit [Member]
Subsequent Event [Line Items]
Debt instrument, basis spread on varaible rate										2.00%
Acquisition [Member] \| Enobia Pharma, Inc. [Member]
Subsequent Event [Line Items]
Business acquisition, cash paid										$ 610,000
Percentage of capital stock acquired										100.00%
Business acquisition, additional contingent payments										$ 470,000
Accrued professional fees							$ 2,039

Quarterly Financial Information (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2011

Sep. 30, 2011

Jun. 30, 2011

Mar. 31, 2011

Dec. 31, 2010

Sep. 30, 2010

Jun. 30, 2010

Mar. 31, 2010

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

May 20, 2011

$ 227,559

$ 204,047

$ 185,699

$ 166,126

$ 155,976

$ 141,569

$ 125,834

$ 117,578

$ 783,431

$ 540,957

$ 386,800

Cost of sales

28,798

23,369

21,745

19,228

20,222

16,495

13,721

13,999

93,140

64,437

45,059

Operating expenses

123,391

^[1]

114,479

^[1]

114,930

^[1]

106,665

^[1]

90,724

82,361

79,788

73,009

459,465

325,882

254,682

Operating income

75,370

66,199

49,024

40,233

45,030

42,713

32,325

30,570

230,826

150,638

87,059

$ 48,170

$ 65,570

$ 34,745

$ 26,830

$ 26,450

$ 27,873

$ 21,773

$ 20,934

$ 175,315

$ 97,030

$ 295,166

Earnings per common share

$ 0.26

^[2]

$ 0.36

^[2]

$ 0.19

^[2]

$ 0.15

^[2]

$ 0.15

^[2]

$ 0.16

^[2]

$ 0.12

^[2]

$ 0.12

^[2]

$ 0.96

^[3]

$ 0.54

^[3]

$ 1.73

^[3]

Percent of common stock dividend

$ 0.25

^[2]

$ 0.34

^[2]

$ 0.18

^[2]

$ 0.14

^[2]

$ 0.14

^[2]

$ 0.15

^[2]

$ 0.12

^[2]

$ 0.11

^[2]

$ 0.91

^[3]

$ 0.52

^[3]

$ 1.63

^[3]

100.00%

Acquisition-related costs

$ 9,928

$ 13,486

$ 722

$ 0

[1]	Included within operating expenses for the first quarter 2011 are acquisition-related costs of $9,928 associated with the Taligen and Orphatec acquisitions.
[2]	On May 20, 2011, we effected a two-for-one stock split, paid in the form of a 100% stock dividend. Stockholders of record at the close of trading on May 2, 2011 were issued one additional share of common stock for each share owned by such shareholder. All per share data presented in the accompanying table has been retroactively restated to reflect the stock split.
[3]	Reflects the May 20, 2011, two-for-one stock split (refer to Note 1 for further discussion)

Label	Element	Value
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	us-gaap_DefinedBenefitPlanFairValueOfPlanAssets	$ 9,542,000
Real Estate [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	us-gaap_DefinedBenefitPlanFairValueOfPlanAssets	1,214,000
Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	us-gaap_DefinedBenefitPlanFairValueOfPlanAssets	4,934,000
Cash and Cash Equivalents [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	us-gaap_DefinedBenefitPlanFairValueOfPlanAssets	921,000
Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	us-gaap_DefinedBenefitPlanFairValueOfPlanAssets	$ 2,473,000